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The progression of the cell cycle is a tightly regulated process, regulated by the 
activities of cyclin dependent kinases. Phosphorylation of target proteins regulates key 
transitions in the cell cycle contributing to accurate DNA replication and cell division. 
Here we evaluate the regulation of the protein Ciz1 by cyclin A-CDK2. 
Ciz1 promotes localisation of cyclin A-CDK2 to chromatin sites at the G1/S phase 
transition and this ternary complex promotes initiation of DNA replication. However, 
the mechanisms by which Ciz1 is regulated are not fully understood. Here, Ciz1 
protein levels are shown to be reduced after inhibition of CDK activity, suggesting 
that CDK-mediated phosphorylation of Ciz1 could contribute to increased protein 
stability.  
As Ciz1 is known to be a substrate of cyclin A-CDK2, enzyme kinetic studies were 
performed to evaluate whether there is preferential phosphorylation at specific sites 
within Ciz1. We characterise new phospho-specific antibodies that will be of benefit 
in future in in vivo studies evaluating the role of phosphorylation at specific sites in 
regulation of Ciz1 function. 
Using His-ubiquitin, we show that Ciz1 is covalently linked to ubiquitin. These 
complexes are stabilised after inhibition of the proteasome, consistent with 
degradation by the proteasomal. Further evidence presented demonstrates that an E3 
ligase (Cdh1) interacts with Ciz1 via a conserved destruction box in the N-terminus. 
Taken together, the data presented here suggest that Ciz1 is regulated at multiple 
levels post-transitionally that contribute to ensuring it accumulates precisely at the 
G1/S phase transition. This may have important implications for its role as a driver 
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1.1 AN INTRODUCTION TO THE CELL CYCLE 
The cell cycle consists of four major phases and is strictly regulated by a large number 
of factors such as fibroblast growth factors (Dailey et al., 2005). Failure in the control 
of this process can have drastic consequences; such as uncontrolled cell proliferation, 
leading to cancer (Welcker and Clurman, 2008). The cell cycle is divided into four 
phases: the G1, S, G2 and M phases (Cho et al., 1998). However, there is an additional 
stage that describes the non-replicative state that over 95% of cells enter between cell 
cycle divisions that is referred to as G0 or quiescence (Pardee, 1974, Cheung and 
Rando, 2013). A cell must commit to entering the cell cycle after mitosis or 
quiescence; the specific occurrence of which is known as the restriction point (R), first 
defined as the stage in the cell cycle at which nutrition levels in the cell are optimum 
to allow the cell cycle to progress (Pardee, 1974). Many different factors including 
growth factors lead to the activation of downstream pathways. One protein activated 
in this process is Ras, which sends signals further along down several different 
pathways (Goodsell, 1999). One such pathway results in the expression of cyclin D1 
and suppression of the CDK inhibitor p27
Kip1
 (Aktas et al., 1997). In this way, cells 
can progress through the G1 phase due to the presence of cyclin D1 and the removal of 
the inhibition of CDKs by p27
Kip1
. The primary factors that drive cell cycle 
progression are two protein families known as cyclins and cyclin-dependent kinases 
(CDKs) (Murray, 2004, Sánchez and Dynlacht, 2005).  
There are four main cyclins that regulate cell cycle progression. Each cyclin binds to 
its appropriate cognate partner, leading to the activation of its kinase activity and 
phosphorylation of its target substrates (Jeffrey et al., 1995, Obaya and Sedivy, 2002). 
A diagram of the cell cycle showing the four stages together with the accompanying 
cyclin-CDK complexes is shown in Figure 1. 
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As indicated by their name, CDKs phosphorylate multiple substrates leading to a 
number of consequences including both activation and inactivation of proteins; the 
consequences of which cause the progression of the cell cycle and also ensure that the 
cell does not revert back to an earlier stage (Bloom and Cross, 2007). This forward 
only direction of the cell cycle is in part aided by the removal of proteins once their 
functions are no longer required by the cell. Many proteins are degraded by the 
ubiquitin proteasome system, with ubiquitin ligases targeting specific substrates only. 
This ensures that the correct proteins are removed from the system at the correct time 
(Lecker et al., 2006). 
After mitosis has occurred, cells enter either quiescence (G0) or the G1 phase during 
which the cell prepares to enter the next stage known as the S phase. There are two 
main G1 phase cyclins, each of which bind to distinct CDKs and perform different 
 
Figure 1: Regulation of the cell cycle by cyclin-CDK complexes 
Each stage of the cell cycle is tightly regulated by a specific CDK molecule 
complexed with its partnering cyclin. These complexes ensure that each stage of the 
cell cycle progresses smoothly and is complete before the cell is allowed to enter the 
next stage (Vermeulen et al., 2003). 
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functions. These are cyclin D, which binds to CDK4 or CDK6 and is largely 
responsible for progression through the G1 phase (Meyerson and Harlow, 1994) and 
cyclin E, which binds CDK2 and is active later in the G1 phase as it is responsible for 
transitioning to the S phase (Ohtsubo et al., 1995). 
Cyclin D binds to either CDK4 or CDK6 and is involved in promoting the progression 
through the R point, requiring sustained extracellular signal regulated kinase (ERK) 
activity, which can be induced in Chinese hamster embryo fibroblasts by the presence 
of platelet-derived growth factor (PDGF) (Foster et al., 2010, Weber et al., 1997). 
Cyclin E binds to CDK2 and commits the cell to DNA replication by removing 
suppression of the transcription factor E2F, which is responsible for the expression of 
several genes required for the cell to enter the S phase (Foster et al., 2010). Once this 
stage has been passed, the cell can no longer return to G1. The main suppressor of E2F 
is the retinoblastoma protein (pRb) family that consists of the pocket proteins p105, 
p107 and p130 containing A and B subdomains, separated by a highly conserved 
spacer region that allows these subdomains to assemble into a pocket-like structure 
(Giordano et al., 2007). As the cell cycle progresses through the G1 phase, pRb is 
phosphorylated by cyclin D-CDK4/6, removing suppression of E2F (Baker et al., 
2005) and then cyclin E-CDK2 forming a positive feedback loop (Giacinti and 
Giordano, 2006). In this way, pRb limits cell cycle progression until cyclin D-CDK4/6 
activity is high enough. This activity is determined by levels of mitogenic signalling 
(Carpenter and Cohen, 1990, Massagué et al., 2000, Aktas et al., 1997). 
Both cyclin E and cyclin A are required for S phase entry and activity, unlike other 
cyclins. This was first shown in Xenopus egg extracts where DNA replication ability 
was assessed in the presence and absence of cyclin-CDK complexes (Strausfeld et al., 
1996). Cyclin A binds CDK2 during the S phase and is required for DNA replication 
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as it is responsible for activating the replication complexes assembled on DNA 
(Coverley et al., 2002). Part of this activation occurs when cyclin A-CDK2 
phosphorylates Cdc6, a member of the pre-replication complex. This phosphorylation 
causes Cdc6 to re-localise to the cytoplasm, suggesting that this also contributes to 
prevention of re-replication (Petersen et al., 1999). However, more recently, cyclin A 
has also been found to bind CDK1, with levels of cyclin A bound to CDK1 or CDK2 
rising during S phase and continuing until almost the end of the G2 phase. These 
complexes are required for DNA replication as well as preparing the cell for mitosis 
such as organisation of centrosomes (Hochegger et al., 2008, De Boer et al., 2008).  
High CDK activity during DNA replication also functions to prevent re-replication. 
This is achieved by phosphorylation of pre-replication complex components, thus 
inhibiting their assembly onto DNA, preventing the formation of new sites on DNA 
where replication can be initiated (Arias and Walter, 2007). Cyclin A-CDK2 is 
responsible for activating cyclin B-CDK1 associated with centrosomes and for 
translocating other pools of cyclin B-CDK1 to the nucleus. In this way, cyclin A-
CDK2 regulates the timing of entry into the M phase (De Boer et al., 2008). 
Duplication of centrosomes has also been shown to require cyclin-CDK2 activity 
although the exact mechanism for this process is not understood (Lacey et al., 1999, 
Matsumoto et al., 1999, Tsou and Stearns, 2006).  
During the G2 phase, re-replication of DNA continues to be inhibited by cyclin B-
CDK1 in several ways including down-regulating Cdc6 activity (Nguyen et al., 2001) 
and the cell prepares to enter the M phase where mitosis occurs. Entry into the M 
phase requires activation of p34
cdc2
 (Nurse, 1990). Shortly before this stage is reached; 
levels of cyclin B bound to CDK1 rise; with complexes initially located at the 
centrosomes (Jackman et al., 2003). Activation of these complexes results in the 
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centrosomes being separated and the cyclin B-CDK1 complexes themselves are 
translocated to the nucleus where mitosis initiates with the degradation of the nuclear 
envelope and the condensing of the chromosomes (Takizawa and Morgan, 2000). The 
mitotic spindles are also formed; completing the events of metaphase. Once these 
events have occurred, the cyclin B-CDK1 complexes are degraded by the anaphase 
promoting complex/cyclosome (APC/C) E3 ubiquitin ligase during anaphase 
(Hochegger et al., 2008), resulting in low levels of CDK activity. Mitosis then 
concludes with new daughter cells formed; at which stage the cells can either enter 
quiescence (G0) or enter the cell cycle (G1) once again.  
Re-entry into G1 requires continued mitogenic signalling which leads to production of 
increased CDK activity to avoid entry into a quiescent state (Spencer et al., 2013). 
Cyclin expression is dependent on the stage of the cell cycle which is determined by 
the activity of the cyclin expressed previously except for cyclin D expression, which is 
dependent on mitogenic signalling. CDKs are relatively stable and are generally 
constitutively expressed. However, their activity is limited by cyclin expression. This 
means that between the degradation of cyclin B at the end of mitosis and the 
expression of cyclin D at the beginning of G1, CDK activity is very low (Obaya and 
Sedivy, 2002). Levels of cyclin proteins are also determined by their degradation. 
Exit from mitosis requires inactivation of mitotic cyclins. This has been shown to 
require Cdc14 phosphatase activity, which among other functions, is thought to be 
responsible for dephosphorylating Cdh1, an activator protein that forms part of the E3 
ligase APC/C complex and is responsible for mitotic cyclin degradation. Cdc14 is also 
responsible for dephosphorylating Sic1, a CDK inhibitor, resulting in this protein no 
longer being marked for degradation (Visintin et al., 1998). The APC/C is also 
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responsible for the degradation of cyclin A when the cell first enters mitosis (Geley et 
al., 2001). 
The G1 phase involves assembling all the machinery required for DNA replication; the 
pre-replication complex followed by the pre-initiation complex which bind to DNA 
and contain the proteins required for DNA replication (Diffley and Labib, 2002, Blow, 
2001). This occurs during the S phase; with the G1/S checkpoint forming a control that 
ensures all components are present and correctly assembled before the cell is allowed 
to enter the replicative phase. One protein that forms part of this checkpoint is 
Cdc25A phosphatase. This is responsible for removing the inhibitory 
phosphorylations of CDK2, thus allowing increased CDK activity. However, if the 
DNA is damaged, the ATM pathway is activated, leading to reduced Cdc25A activity. 
As a result, the inhibition of CDK2 is not removed and the cell cycle cannot progress 
(Donzelli and Draetta, 2003).  
The pre-replication complex is formed on DNA where origin recognition complexes 
(ORC) are located (Evrin et al., 2009). It consists of a replicative DNA helicase 
composed of six members of the MCM (minichromosome maintenance) protein 
family (MCM2-7) (Bochman and Schwacha, 2008), MCM9, Cdt1, which is required 
for loading of the MCM2-7 complex (Lutzmann and Mechali, 2008, Rialland et al., 
2002)and Cdc6 (Sacco et al., 2012). Activation of this complex leads to the formation 
of the pre-initiation complex, consisting of other proteins including Cdc45 and the 
GINS complex (Walter and Newport, 2000, Sacco et al., 2012). This ultimately leads 
to recruitment of DNA polymerases and the formation of the replication fork (Waga 
and Stillman, 1998, Heller et al., 2011, Leman and Noguchi, 2013). All activation 




1.2 THE UBIQUITIN-PROTEASOME SYSTEM (UPS) 
The ubiquitin proteasome system is composed of a large network of proteins that work 
together to degrade proteins. This serves a number of purposes including protein 
homeostasis and regulation of transitions in the cell cycle (Lecker et al., 2006, 
Nakayama and Nakayama, 2006). As this system is irreversible, it must be tightly 
regulated to ensure that a correct balance exists between degradation and synthesis 
and that specific proteins are only degraded when required (Lecker et al., 2006).  
Proteasome substrates are marked with multiple ubiquitin chains that are conjugated 
to target protein that mark them for degradation. Ubiquitin is a highly conserved 
protein found in eukaryotes that covalently attaches to other proteins using the glycine 
residue at the C terminus in ubiquitin and a lysine residue in the target protein 
(Hershko et al., 1984, Chau et al., 1989, Kerscher et al., 2006). However, binding of 
further ubiquitin monomers can occur at distinct lysine residues. Depending on which 
of these residues is used to form poly-ubiquitin chains; the purpose of this chain varies 
(Pickart, 2001). Early studies performed in the 1980’s using β-galactosidase, a protein 
known to be ubiquitylated, revealed that binding of the first ubiquitin monomer to the 
substrate only occurs at certain specific lysine residues. In addition, the poly-ubiquitin 
chain that targeted the substrate to the 26S proteasome was formed by bonds between 
the residues glycine 76 and lysine 48 between individual ubiquitin monomers 
(Hershko et al., 1984, Chau et al., 1989). However, if poly-ubiquitin chains are formed 
using the lysine 63 residue instead, the function of this lysine 63-linked chain seems 
not to be to target the substrate to the 26S proteasome but as something different such 
as to act as a signalling mechanism (Pickart, 2001, Li and Ye, 2008). More recently, 
other lysine linkages have been observed (Fig. 3) (Dikic et al., 2009). Three classes of 
enzymes are involved in the ubiquitylation process: the E1, E2 and E3 enzymes 
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(Scheffner et al., 1995). Ubiquitin molecules are attached to E1 activating enzymes 
before being transferred to E2 conjugating enzymes. The activated ubiquitin is then 
transferred to the substrate by the E3 ligase (Fig. 2). 
 
Figure 2: The enzyme cascade resulting in substrate ubiquitylation (Dikic et al., 
2009) 
(A) The activation of ubiquitin monomers and their transfer to the substrate. (B) 
Ubiquitin monomers can form chains using different linkages. This can act as a 
signalling system in itself to denote a function. 
Eight E1 enzymes that are known to initiate conjugation of ubiquitin or ubiquitin like 
proteins have been identified in humans. Activation of ubiquitin occurs in two steps. 
E1 first catalyses acyl-adenylation of the C-terminus of ubiquitin before this structure 
is attacked by a catalytic cysteine residue within E1 that causes the formation of the 
activated ubiquitin complexed with the E1 by a thioester bond (Haas et al., 1982) 
(‘Activating’, Fig. 2A). This process requires ATP. The activated ubiquitin protein 
can then be transferred to an E2 conjugating enzyme when E1 and E2 physically 
associate; allowing the C terminus of ubiquitin to be transferred to the catalytic 
cysteine residue of the E2 enzyme (Schulman and Harper, 2009) (‘Conjugating’, Fig. 
2A). Studies have revealed that before ubiquitin can be transferred to the substrate by 
E3 from E2, E2 must first be dissociated from E1 (Eletr et al., 2005). E3 enzymes 





such as amino acid sequence or phosphorylation events. As such, there are over 1000 
E3 ligases (Lin and Mak, 2007, Jackson and Xiong, 2009). Binding of the substrate 
and the E2 conjugating enzyme occurs simultaneously and at separate sites (Berndsen 
and Wolberger, 2014) (‘Ligating’, Fig. 2A). However, transfer of ubiquitin to the 
substrate occurs differently depending on the type of E3 ligase. For example, those 
with a RING finger domain bring the E2 and substrate close together, allowing 
ubiquitin to be transferred directly from the E2 to the substrate whereas those with a 
HECT domain transfer the ubiquitin first to a cysteine residue within the E3 before 
completing the transfer to the substrate. This leaves a substrate with one ubiquitin 
monomer attached. This cycle can then be repeated forming poly-ubiquitin chains 
using different lysine residues to form the links between monomers or can end, 
leaving a mono-ubiquitylated substrate (Fig. 2B). Polyubiquitylated substrates are 
recognised by the 26S proteasome (Figs. 3A and B) and degraded (Glickman and 
Ciechanover, 2002, Lecker et al., 2006). 
The main complex used by this system responsible for the breakdown of proteins is 
the 26S proteasome (Bedford et al., 2010). The 26S proteasome is composed of two 
subunits: the core particle (CP, 20S) and the regulatory particle (RP, 19S) (Fig. 3C). 
Substrates are first recognised by and enter the RP where they are deubiquitylated and 
unfolded in an active process that requires ATP before they are transported to the CP 
where peptidases aid in protein breakdown and single amino acids or short amino acid 
chains are released and are either recycled or used for antigen presentation (Fig. 3C) 
(Hochstrasser, 2009). The exact mechanisms used to perform these tasks are unclear 
but conformational changes have been associated with the function. Assembly of this 
structure is very precise and is tightly regulated by a number of chaperones whose 
specific functions are to ensure the correct assembly of the final product. These 
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chaperones are thought not to be involved in the function of the 26S proteasome 
(Bedford et al., 2010). 
1.3 E3 LIGASES CONTRIBUTE TO CONTROL OF CELL CYCLE 
PROGRESSION 
The two principle E3 ligases responsible for the degradation of proteins involved in 
regulating the cell cycle are the Anaphase Promoting Complex / Cyclosome (APC/C) 
and the Skp, Cullin, F-box containing (SCF) complex and are active during distinct 
stages of the cell cycle (Vodermaier, 2004, Castro et al., 2005). Considering that 
progression of the cell cycle is tightly regulated; the functions of these two E3 ligases 
must also be tightly regulated.  
 
Figure 3: Pathway of a 26S proteasome substrate (Hochstrasser, 2009) 
(A) Substrates are marked for degradation by poly-ubiquitylation. (B) Substrates are 
recognised by the 26S proteasome. (C) The 26S proteasome degrades the substrate 
and releases ubiquitin monomers.  
 
A B C 
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SCF complexes recognise their substrates using the F-box protein which confers 
specificity. This requires specific modifications of the substrate at specific sites such 
as phosphorylation (Wang et al., 2014b). Phosphorylation of proteins by cyclin 
dependent kinases (CDK) is known to have several possible effects. For example, in 
the late G1 phase, Cdh1; a protein that can form part of the APC/C complex, activating 
it and conferring specificity (Castro et al., 2005); is phosphorylated by CDKs causing 
it to dissociate from the APC/C complex and is then recognised by the SCF
β-TRCP
 
complex and ubiquitylated, marking it for degradation (Fig. 4B) (Kramer et al., 2000, 
Fukushima et al., 2013). In this way, the SCF complex regulates the APC/C complex 
and inactivation of APC/C
Cdh1





 during the earlier stages of the G1 
phase by ubiquitylating Skp2, causing its degradation (Fig. 4A). As the cell cycle 
progresses towards the G1/S phase transition, Skp2 is phosphorylated first by cyclin E-
CDK2 and then cyclin A-CDK2. Skp2 itself regulates the activity of the CDK 
inhibitor proteins p21, p27 and p57 which, when active, inhibit cyclin E-CDK2, 
forming a positive feedback loop. These phosphorylation events increase protein 
stability, preventing ubiquitylation by APC/C
Cdh1
 and so Skp2 is no longer degraded 
(Fig. 4B) (Rizzardi and Cook, 2013, Vodermaier, 2004). This demonstrates that not 
only do SCF and APC/C regulate each other (Fig. 4), but that phosphorylation of 
proteins can either function as a mark for degradation or alternatively, protect against 
degradation (Wang et al., 2014b, Rizzardi and Cook, 2013). It is the combination of 
these events that ensure proteins are ubiquitylated and degraded during the correct 
stages of the cell cycle. 
The APC/C complex recognises its substrates via specific sequences. It also requires 
the presence of an activating protein which simultaneously confers specificity. During 
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the initial stages of mitosis, Cdc20 binds to APC/C; causing ubiquitylation of 
substrates containing an RXXL motif, subsequently referred to as the destruction box 
(D-box). However, as most substrates of APC/C
Cdc20
 are required for mitotic spindle 
assembly until the checkpoint has been passed and Cdc20 is unable to bind activate 
APC/C during this stage since it forms part of the mitotic checkpoint complex (MCC); 
an alternative form of recognising substrates such as cyclin A that are degraded before 
this point by APC/C
Cdc20
 is required. Cyclin A has been found to contain a motif that 
binds Cdc20, allowing its degradation (Di Fiore et al., 2015). This motif has also been 
found in other proteins that form part of the MCC and studies have suggested that the 
motif, named ABBA, results in competitive binding between cyclin A and the MCC 
components with Cdc20 (Di Fiore et al., 2015). Cdh1 activates APC/C during late 
mitosis until late G1 (Kramer et al., 2000, Li and Zhang, 2009) and recognises its 
substrates either by the D-box or the KEN box. Cdc20, a substrate of APC/C
Cdh1
, is 
recognised by the KEN box (Pfleger and Kirschner, 2000). 
 
Figure 4: The APC/C and SCF complexes regulate each other during different 
stages of the cell cycle (Fasanaro et al., 2010) 




 levels. (B) During late G1, 
SCF
Skp2
 becomes the more dominant E3 ligase and Cdh1 is marked for degradation. 
(C) When the cell enters the M phase, APC/C becomes active once again, this time 




It is known that APC/C
Cdh1
 ubiquitylates substrates in a specific order (Buschhorn and 
Peters, 2006). It has been hypothesised that there are two methods used to ubiquitylate 
proteins depending on when the functions of these substrates are required in the cell 
cycle. Substrates degraded during late mitosis and the early G1 phase are ‘early’ 
substrates. These are bound by APC/C
Cdh1
 and are quickly poly-ubiquitylated. ‘Late’ 
substrates are continuously bound and unbound by the APC/C complex and are at first 
mono-ubiquitylated, due to preferential binding to ‘early’ substrates. Deubiquitylating 
enzymes can remove these ubiquitin monomers. As the cell progresses through G1, 
competition in the form of ‘early’ substrates is removed and the ‘late’ substrates are 
bound more often by APC/C
Cdh1
. This leads to poly-ubiquitylation and subsequent 
degradation of the substrate. Binding of APC/C
Cdh1
 to substrates is greatly influenced 
by the D-box (Rape et al., 2006). 
1.4 EMERGING ROLE OF THE UPS IN CANCER BIOLOGY 
The importance of the SCF and APC/C complexes being tightly regulated is 
highlighted when mutations of certain components of these complexes occurs. 
Mutations of associated genes can lead to a variety of cancers. For example, Skp2 has 
been observed to be overexpressed in several cancers such as lung cancers and breast 
cancers. This overexpression has many consequences since Skp2 targets several 
substrates including p27, a CDK inhibitor, as well as several cyclins (Nakayama and 
Nakayama, 2006, Wang et al., 2014b). Another example is the reduced expression of 
Cdh1 in the malignant progression of a B lymphoma cell line. This again has drastic 
consequences as APC/C
Cdh1
 is responsible for degrading several inhibitors of pre-RC 
assembly such as mitotic cyclins and Skp2. These inhibit pre-RC assembly by 
inhibiting high cyclin-CDK activity, which when elevated, could lead to premature 
activation and entry into S phase (Nakayama and Nakayama, 2006). 
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Other minor E3 ligases can also contribute to cancer development and progression 
such as the Human double minute 2 (Hdm2), an E3 ligase made up of a single protein. 
Overexpression of this protein has been observed in several cancer types including 
breast carcinomas and malignant melanomas (Sun, 2003, Yin et al., 2005). Hdm2 is 
responsible for binding to p53 and causing its ubiquitylation, leading to the eventual 
degradation. When Hdm2 is overexpressed p53 degradation is excessive (Sun, 2003) 
and since p53 is responsible for a number of functions including apoptosis and cell 
cycle progression; loss of p53 leads to deregulation of the cell cycle, eventually 
resulting in cancer (Kastan et al., 1995). 
Mutated E3 ligases have been observed in many cancer types. These involve those 
that are directly responsible for ubiquitylating proteins that regulate progression of the 
cell cycle such as SCF
Skp2
; a target of which includes p27, a CDK inhibitor 
responsible for inhibiting cell cycle progression (Nakayama and Nakayama, 2006, 
Wang et al., 2014b); but also include those that are indirectly responsible for cell cycle 
regulation such as Hdm2 (Sun, 2003) and HECTH9, responsible for ubiquitylation of 
the transcription factor Myc and has been observed to be over-expressed in a number 
of cancers causing Myc-induced cell proliferation (Adhikary et al., 2005). For this 
reason, E3 ligases have been investigated as potential cancer therapy targets. Initially, 
the 26S proteasome was considered the ideal target for inhibition; however it was 
considered by many that this treatment type would be highly toxic to normal cells as 
well. Surprisingly, it was quickly observed that cancer cells are highly susceptible to 
proteasomal inhibition, ultimately resulting in cell death (Rizzardi and Cook, 2013).  
More recently, E3 ligases as targets of cancer therapy have been investigated. One 
such E3 ligase is the murine double minute 2 (Mdm2) (Vassilev, 2007). As stated 
previously, Mdm2 is responsible for ubiquitylation of p53 and has been observed to be 
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over-expressed in certain cancers (Sun, 2003, Yin et al., 2005). Inhibitors of Mdm2 
ubiquitin ligase activity have been found to have low potency and selectivity. 
However, inhibitors of the Mdm2-p53 interaction such as the nutlins have been found 
to show more promise as they have a higher specificity and potency and when 
administered to cultured cells, have been shown to lead to activation of the p53 
pathway due to increased protein stability. Other small molecule inhibitors have also 
been identified although nutlins remain the most promising (Vassilev, 2007). Skp2 has 
also been investigated as a target of small molecule inhibitors; with two compounds 
identified as Compound A, which induces apoptosis and cell cycle arrest in multiple 
myeloma cells; and SZL‑P1‑41, which suppresses E3 ligase activity of Skp2 but no 
other SCF components (Wang et al., 2014b). 
1.5 CIZ1 PROMOTES CELL CYCLE PROGRESSION 
The CIZ1 gene is located at 9q34.1 (Gilley and Fried, 1999). Ciz1 has been 
functionally linked to regulation of the cell cycle and directly associates with several 
cell cycle regulators including p21
Cip1/Waf1
 (Mitsui et al., 1999), cyclin A and cyclin E 
(Copeland et al., 2010b) and CDK2 (den Hollander and Kumar, 2006). The protein 
has been found to bind to the N-terminal region of p21
Cip1/Waf1
, which is the same 
region that binds to CDK2, indicating that this binding occurs in a competitive 
manner. Binding affinities of p21
Cip1/Waf1
, CDK2 and Ciz1 show that p21
Cip1/Waf1 
binds 
CDK2 preferentially. This interaction involves the first of three zinc finger motifs, 
with initial studies indicating that Ciz1 is also responsible for regulating the location 
of p21
Cip1/Waf1 
within the cell. In the absence of Ciz1, p21
Cip1/Waf1 
is largely located in 
the nucleus whereas when bound to Ciz1, the complex formed is mainly found in the 
cytoplasm; indicating that Ciz1 not only competitively binds the CKI in place of 
CDK2 but also sequesters it away from the nucleus: the site of pre-RC and pre-IC 
17 
 
formation (Mitsui et al., 1999). It was also found that p21 binding is dispensable for 
Ciz1 function in promoting cell cycle progression using p21 null fibroblasts (Coverley 
et al., 2005) suggesting that Ciz1 does not promote cell cycle progression solely by 
sequestering the CDK inhibitor p21
Cip1/Waf1
 in the cytoplasm. 
More recently, Ciz1 has been shown to promote cellular proliferation through 
stimulation of initiation of DNA replication in cell-based and cell-free assays. This 
function is independent of the interaction of Ciz1 with p21 as both p21
Cip1
 null cells as 
well as wild type cells showed this stimulation in the presence of Ciz1(Coverley et al., 
2005). It also explains the observation that Ciz1 is largely located at sites of initiation 
of DNA replication within the nucleus rather than in the cytoplasm. A more focussed 
study on Ciz1 localisation revealed that the C-terminal domain encodes a tag for the 
nuclear matrix localisation, whereas the N-terminal domain contains the replication 
domain and is therefore responsible for localisation at DNA replication specific foci 
(Coverley et al., 2005, Ainscough et al., 2007). Results obtained suggest that Ciz1 
plays a role in the later stages of the G1 phase after formation of the pre-RC is 
complete by recruiting cyclin A to these sites of DNA replication (Copeland et al., 
2010b). This allows activation of DNA replication due to increased cyclin A-CDK2 
activity; causing phosphorylation of several proteins (Petersen et al., 1999, Lei and 
Tye, 2001). 
In the study by Coverley et al. (2005), a link between cyclin A-CDK2 and Ciz1 was 
discovered, suggesting that Ciz1 may also have a function during the S phase. 
However, the precise relationship between the two was not elucidated. Since then, 
further investigations have revealed that Ciz1 functions in conjunction with cyclin A-
CDK2 to activate DNA replication (Copeland et al., 2010a). 
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Subjecting replication-competent nuclei to recombinant cyclin A-CDK2 within a 
specific concentration range results in a larger number of nuclei where DNA 
replication is initiated in vitro than in the absence of this complex. A similar effect is 
observed when adding recombinant embryonic Ciz1 (ECiz1), which differs slightly 
from Ciz1 due to alternative splicing in exons 2/3, 6 and 8 (Coverley et al., 2005, 
Copeland et al., 2010a). However, when ECiz1 is added together with recombinant 
cyclin A-CDK2, the concentration range at which recombinant cyclin A-CDK2 
stimulates initiation of DNA replication becomes larger, expanding at both ends of the 
scale (Copeland et al., 2010a). These observations support those previously made, 
whilst also providing further evidence of a relationship between Ciz1 and cyclin A-
CDK2.  
Ciz1 has been shown to directly bind both cyclin E and cyclin A using a Cy motif, 
located close to the CDK-binding domain (Copeland et al., 2010b). This Cy motif is a 
cyclin-binding sequence and is found in inhibitors, activators and substrates of CDKs, 
including p21
Cip1/Waf1
 (Wohlschlegel et al., 2001). Ciz1 has 3 Cy motifs located within 
the N-terminal domain: the region containing the replication domain. The second 
motif has been found to be essential for function as mutations within this sequence 
result in an inability to influence DNA replication; which could be due to the impaired 
binding with both cyclin A and cyclin E when mutations in this region are present. 
Binding of Ciz1 to cyclin A and cyclin E is not identical (Copeland et al., 2010a); as 
might be possible to occur when considering levels of these cyclins do not reach their 
peaks during the same stage of the replication cycle. Evidence has shown that as 
cyclin A levels increase as the cell enters the S phase; cyclin E, whose levels are 
highest during the second part of the G1 phase; is displaced from Ciz1 which in turn, 
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binds to cyclin A. This could mean that cyclin A is partly responsible for the 
displacement of cyclin E from Ciz1 (Copeland et al., 2010b).  
The influence of Ciz1 on cyclin A-CDK2 activity was shown when small interfering 
RNA (siRNA) against Ciz1 transcripts was added during the G1 phase, effectively 
reducing Ciz1 protein levels. This led to a significant reduction in recruitment of 
cyclin A to the nucleus, resulting in the number of cells entering S phase to be greatly 
reduced. It was also shown that a reduction in Ciz1 levels did not affect recruitment of 
cyclin E. Together with the observation that cyclin A displaces cyclin E from Ciz1, 
this strongly suggests that Ciz1 first binds to cyclin E which is located at specific foci 
within the nucleus, then recruits cyclin A to these foci and exchanges binding partners 
(Copeland et al., 2010a). 
It is clear that Ciz1 is somehow involved in the initiation process of DNA replication. 
Evidence suggests that Ciz1 has a regulatory role in this process as low levels of this 
protein have been shown to have a detrimental effect on the recruitment of cyclin A-
CDK2 to the required locations, resulting in the inhibition of the initiation of DNA 
replication. Further evidence of a regulatory role is shown in certain cancers where 
Ciz1 is mutated (Nishibe et al., 2013). Other binding partners such as p21
Cip1/Waf1
, a 
known inhibitor of cyclin E-CDK2 that is normally sequestered unless activated as 
part of the DNA damage response, also support this (Sherr and Roberts, 1999, 
Satyanarayana et al., 2008). It has also been shown that the knockdown of Ciz1 results 
in reduced CDK2 activity (den Hollander and Kumar, 2006); revealing that not only is 




More recent evidence has provided more evidence of the relationship between cyclin 
A-CDK2 and Ciz1. This evidence has shown that not only are cyclin A-CDK2 and 
Ciz1 binding partners, but that Ciz1 is actually also a substrate of this cyclin-CDK 
complex. Phosphorylation at threonine residues 144, 192 and 293 result in the direct 
interaction between Ciz1 and cyclin A-CDK2 to be blocked, resulting in cyclin A no 
longer being recruited to sites of DNA replication. However, Ciz1 nuclear matrix 
localisation is retained. Phospho-specific antibodies monitoring Ciz1 phosphorylation 
status demonstrated that Ciz1 is not phosphorylated until mid-S phase, suggesting that 
cyclin A-CDK2 plays a role in inhibiting re-replication of DNA as formation of the 
replisome no longer occurs when Ciz1 is phosphorylated at these sites (Copeland et 
al., 2015). This also provides evidence that Ciz1 is one of the many factors involved in 
ensuring that DNA replication and the preparation for this event beforehand occurs 
when kinase levels are relatively low. 
1.6 ALTERNATIVE FUNCTIONS OF CIZ1 
Ciz1 is expressed at varying levels in a wide range of tissues, indicating that this 
protein is not just required for a specific cell type, but is rather utilised more generally. 
This emphasises the role of Ciz1 during the generic cell cycle; although varying levels 
of expression indicate that regulation of this protein does differ depending on cell 
type. The tissues in which Ciz1 is known to be expressed include the brain, heart, 
placenta, lung, liver, skeletal muscle, kidney and pancreas (Warder and Keherly, 
2003). Ciz1 has since been observed in other tissues as well, including male germ 
cells (Greaves et al., 2012).  
Ciz1 has more recently been found to bind Enhancer of Rudimentary Homolog 
(ERH). Co-expression of these proteins results in Ciz1 recruiting ERH to DNA 
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replication foci (Łukasik et al., 2008). ERH was first identified some years ago as an 
orthologue of a gene found in Drosophila. However, the precise function of this 
protein has still not been fully explained. ERH is known to be located in the nucleus 
and various proteins have been shown to interact with it; the functions of which have 
led to suggestions that ERH is involved in regulating various processes including 
transcription, cell shape and the cell cycle. Compiling all the evidence regarding the 
human orthologue as well as those from other species including Caenorhabditis 
elegans and yeast has led to a complex map of protein-protein interactions. This map 
includes proteins involved in regulating the cell cycle including skpA and skpB 
(components of the SCF complex in Drosophila) which are important components of 
several ubiquitin E3 ligase complexes. It has also been shown that the ERH 
orthologue protein in Drosophila interacts with CDK4 and Rux, a CKI that interacts 
directly with cyclin B (Jin et al., 2007). Considering that Ciz1 has now been shown to 
bind ERH at a site that overlaps the p21
Cip1/Waf1
 binding site, containing the first zinc 
finger; it appears that ERH is recruited to sites of DNA replication by Ciz1 when all 
proteins concerned are at the correct levels, blocking binding between Ciz1 and p21 
(Łukasik et al., 2008). Also, in taking into account the other binding partners of ERH 
as well as their functions; it appears that Ciz1 helps regulate the cell cycle indirectly 
as well. This further supports the hypothesis that Ciz1 binds other proteins using the 
DNA-binding sequence identified previously (Warder and Keherly, 2003). 
It has been shown that Ciz1 interacts together with dynein light chain 1 (DLC1) to 
regulate the oestrogen receptor (ER) and also appears to influence p21
Cip1/Waf1
 
indirectly (den Hollander et al., 2006). DLC1 is best known as a component of 
cytoskeleton signalling as it makes up part of the dynein complex involved in 
trafficking vesicles and organelles along microtubules in a retrograde fashion. 
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However, it has also been found to have functions independent of the motor protein 
complex. Oestrogen influences the cell cycle in multiple ways. More recently, it was 
discovered that overexpression of DLC1 has been found to result in an accelerated G1-
S phase transition in an oestrogen-dependent manner as well as stimulating CDK2 
activity (den Hollander and Kumar, 2006).  
An investigation into the mechanism by which DLC1 influences cell cycle 
progression in response to oestrogen led to protein interaction studies which identified 
DLC1 as a novel binding partner for Ciz1. Following experiments showed that DLC1, 
CDK2 and Ciz1 form a trimeric complex (den Hollander and Kumar, 2006); 
suggesting that Ciz1 is not solely responsible for the reduced kinase activity when its 
levels are low as mentioned previously. Knowing that Ciz1 sequesters p21
Cip1/Waf1
 in 
the cytoplasm, thus allowing CDK activity, experiments were performed in order to 
determine whether DLC1 also plays a role in this process as it was previously shown 
that this protein is located both in the cytoplasm and the nucleus. Results indicated 
that DLC1 is indeed involved in this process leading to a modified model of that 
proposed by Mitsui et al. (1999) in which DLC1 forms a complex with Ciz1 before 
sequestering p21
Cip1/Waf1
 together (den Hollander and Kumar, 2006). 
Following on from the discovery of this interaction as well as the knowledge that 
DLC1 is a coactivator of the ER; targeting it to oestrogen response elements (ERE) 
causing the expression of genes downstream to these sequences as well as genes 
within which EREs are located; further studies revealed that Ciz1 is the other half of 
the activating complex of the ER. It was found that Ciz1 interacts with ER via the 
second glutamine-rich domain located in the N-terminal domain and binds to the 
DNA-binding domain of the ER and that this interaction is enhanced by the presence 
of oestrogen (den Hollander et al., 2006). The fact that Ciz1 binds ER at the DNA-
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binding region provides further evidence that the consensus DNA-binding sequence 
within Ciz1 mentioned previously (Warder and Keherly, 2003), allows this protein to 
interact with other DNA-binding proteins and might even confer a greater specificity 
for certain DNA sequences. 
The CIZ1 gene itself is induced by oestrogen in oestrogen-responsive cell lines. It was 
discovered that within this gene, there are multiple partial and complete EREs located 
upstream of exon 1 and the intron between the first two exons. The two complete 
EREs are located within the first intron. A study of Ciz1 mRNA levels revealed that 
oestrogen only induces CIZ1 expression in the presence of the ER. Chromatin 
Immunoprecipitation assays (ChIP) revealed that ERs are recruited to both complete 
EREs. This was followed by a double ChIP with RNA polymerase II and ER which 
confirmed that both EREs are bound by ER and RNA polymerase II in an oestrogen-
dependent manner, thus inducing expression of the CIZ1 gene (den Hollander et al., 
2006). These studies revealed that Ciz1 acts as a coactivator of ER together with 
DLC1 and is itself induced by oestrogen, which suggests a cycle with each complete 
one resulting in increased levels of mRNA transcripts of genes induced by oestrogen 
including Ciz1 that is also responsible for the activation of the ER; effectively forming 
a positive feedback loop. This process would obviously require a system to monitor 
and limit it to maintain proteins at the correct levels. 
An investigation into the regulation of transcription of glucocorticoid receptors (GR) 
was performed using a chromosome conformation capture based technique since most 
glucocorticoid response elements (GRE) are not located proximal to promoters. The 
GRE chosen for this experiment is responsible for the activation of the lipocalin2 gene 
(LCN2). The screening revealed that this GRE also interacts with the CIZ1 gene 
roughly 30kb upstream. Further studies of the chromosome structure around these two 
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genes revealed a loop, resulting in the two genes being physically close together. 
Following on from this observation, it was then determined that like LCN2, CIZ1 is 
also a glucocorticoid responsive gene. This was shown when glucocorticoids were 
added and transcript levels of both these genes were observed to increase in response 
(Hakim et al., 2009). 
Interestingly, glucocorticoids inhibit the activity of oestrogen by negatively regulating 
the signalling pathway of ERα.  ChIP studies revealed that the glucocorticoid receptor 
(GR) binds to several binding regions normally occupied by ERα when both 
glucocorticoids and oestrogen are present but not when only one of these ligands is 
present. The binding of GR to these regions causes the displacement of ERα from 
these sites and destabilises the complex of ERα and the steroid receptor coactivator 
SRC-3 but binding itself is mediated by ERα. However, as a consequence of the 
displacement of ERα, transcription of genes normally activated by ERα is repressed 
(Karmakar et al., 2013). This phenomenon has revealed a possible target for 
oestrogen-responsive cancers. Considering that CIZ1 has been identified as being both 
an oestrogen responsive gene and a glucocorticoid responsive gene, this suggests that 
despite fluctuations in oestrogen and glucocorticoid levels, production of Ciz1 should 
remain relatively constant. 
1.7 ROLE OF CIZ1 IN CANCER BIOLOGY 
It has been noted that alternative splicing of Ciz1, resulting in a lack of exon 4, occurs 
in Ewing tumour cell lines (Rahman et al., 2007). This alternatively spliced protein no 
longer localises at sites of initiation of DNA replication, although it is still located in 
the nucleus. However it is still able to stimulate replication activity. Since this 
observation was made, alternatively spliced Ciz1 has been observed in several other 
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cancer types. Notably, the variant delta 8-12 lacks key functional sites but was found 
to be over-expressed in many cancer cell lines, including over half of a panel of 
primary lung tumours tested (Rahman et al., 2010). This novel variant could be a 
useful biomarker of certain cancer types. 
A study of Ciz1 in lung cancer found that an alternatively spliced form of Ciz1 (in 
exon 14) was present in 34 out of 35 lung tumours but not in the adjacent tissue. 
Further testing revealed that this variant of Ciz1 could be used as a circulating 
biomarker for early-stage lung cancer (Higgins et al., 2012). This variant of Ciz1 was 
still found to be located at the same foci within nuclei as the normal Ciz1 but as larger 
aggregates and also some localisation at the edge of the nucleus. Depletion of both the 
variant and normal forms of Ciz1 resulted in inhibition of DNA replication in cell 
culture (Higgins et al., 2012). 
Ciz1 has since been shown to function as a tumour suppressor in vivo using Ciz1
-/-
 
mice (Nishibe et al., 2013). Ciz1 has also been shown to play an indirect role in breast 
cancers (Okumura et al., 2011) as well as human colon cancer (Wang et al., 2014a). 
Ciz1 was found to be significantly upregulated in the majority of samples tested. It 
was also found to be a prognostic factor of disease free survival after colectomy in 
patients with colon cancer (Wang et al., 2014a). 
In all cancers where Ciz1 was observed to be altered, over-expression of this protein 
was associated with tumour growth (Rahman et al., 2010, Higgins et al., 2012, Wang 
et al., 2014a). Ciz1 should therefore be considered as a potential target in cancer 
therapy where Ciz1 has been observed to be over-expressed; considering that cell 
culture work has demonstrated that targeted depletion of Ciz1 inhibits cell 
proliferation (Higgins et al., 2012). 
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1.8 POST-TRANSLATIONAL REGULATION OF CIZ1 
Although CIZ1 gene expression has been shown to be regulated in part by the ERE 
and GRE (den Hollander et al., 2006, Hakim et al., 2009), post-translational regulation 
of this protein is not fully understood. 
Ciz1 has been shown to be phosphorylated by ATM kinases as part of the DNA 
damage response; thought to form part of a pathway responsible for regulating cyclin 
E such that cell cycle progression is inhibited. The CKI p27, an inhibitor of cyclin E-
CDK2, and FBW7, a component of the SCF complex that targets cyclin E for 
degradation (Welcker and Clurman, 2008), also form part of this pathway network 
(Matsuoka et al., 2007).  
However, Ciz1 is also phosphorylated as part of normal cell cycle progression by 
CDKs. Studies have shown that Ciz1 interacts with both cyclin E-CDK2 and cyclin A-
CDK2 in a sequential manner (Coverley et al., 2005, Copeland et al., 2010b) although 
binding with cyclin E-CDK2 has as yet an unknown function. More recently, Ciz1 has 
also been shown to be a substrate of cyclin A-CDK2 (Copeland et al., 2015). 
In contrast to the observations that phosphorylation of Ciz1 prevents binding to cyclin 
A-CDK2; it has also been shown that depletion of cyclin A leads to a reduction in 
Ciz1 protein levels; which are recovered with the addition of a proteasomal inhibitor 
MG132 (Fig.5A) (Copeland, unpublished data). This suggests that the cyclin A-CDK2 
complex also stabilises the Ciz1 protein, which actively prevents degradation by the 
ubiquitin proteasome system. In order to determine if Ciz1 could also be destabilised 
by chemical means, addition of roscovitine, a known CDK inhibitor was also used 
(Figs. 5B and C) (Copeland, unpublished data). These results suggest that CDK-
mediated phosphorylation of Ciz1 stabilises this protein. Taken together with the 
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results showing that Ciz1 phosphorylation prevents binding to cyclin A-CDK2; one 
possible reason for the apparent opposite situations presented is that low level 
phosphorylation of Ciz1 at perhaps a different CDK phosphorylation site to those 
involved in cyclin A-CDK2 binding is responsible for protein stability. 
 
Figure 5: Ciz1 is destabilised by reduction of cyclin A-CDK2 and is recovered by 
inhibition of the ubiquitin proteasome system 
Ciz1 levels relative to actin are shown in the accompanying histograms below. Cells were 
harvested four hours post-drug treatment and samples were used for western blots. The anti-
N471 antibody was used to observe Ciz1. (A) Cells were depleted of cyclin A by transfection 
of a synchronised population of cells with a-ccna2 siRNA. Cells were also treated with the 
chemical proteasomal inhibitor MG132 as shown. (B) Cells were treated with a chemical 
CDK inhibitor roscovitine, in an asynchronous population of cells and MG132 as indicated. 









1.9 PROJECT AIMS 
This project aims to better understand how the protein Ciz1 is regulated within the cell 
cycle.  
1. Does CDK-mediated phosphorylation of Ciz1 contribute to protein stability? 
This will be investigated by attempting to chemically destabilise the Ciz1 
protein by targeting CDK activity and attempting to identify which site(s), if 
any, contribute to protein stability when phosphorylated by CDK activity. 
2. Preliminary investigation into the potential E3 ligase that regulates Ciz1 levels 
via UPS. Ciz1 ubiquitylation status will first be investigated followed by in 
vitro protein studies to investigate whether the candidate E3 ligase can bind 
Ciz1. 
3. Characterisation of Ciz1 phospho-specific antibodies and enzymological 
analysis of cyclin A-CDK2 mediated Ciz1 phosphorylation. This will involve 
in vitro protein work to determine whether the site of interest, S331, is a 




























All chemicals used were obtained from Sigma-Aldrich except where stated otherwise. 
2.2 Cell Culture 
Mouse fibroblasts (D3T3) were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% foetal bovine serum and 1x penicillin-
streptomycin-glutamine. These were incubated at 37
o
C in 5% CO2. When confluency 
reached 50-60%, cells were passaged with trypsin-EDTA (Gibco
®
) using a final 1x 
concentration diluted in phosphate buffered saline (PBS) and incubated at 37
o
C until 
the cells no longer adhered to the plate before being split onto fresh plates with 
DMEM; inactivating the
 
trypsin-EDTA. Cells were typically split in a 1:2 or 1:4 ratio. 
Populations of cells were synchronised by growing cells by contact inhibition and 
serum starvation. Cells were cultured until they had reached 100% confluency. At this 
point, fresh media was added and cells were left for a further 48 hours, allowing them 
to enter quiescence. Cells were then released back into the cell cycle by trypsinisation 
as described except 2x trypsin was used to break cell-cell interactions. Cells were 
diluted 1:4 and placed in fresh supplemented DMEM on new plates. If cells were 
transfected, this process occurred when cells were trypsinised. 
Two drugs were used in these experiments: roscovitine (Sigma-Aldrich) and MG132. 
Roscovitine was dissolved in DMSO, with the final concentration ranging between 
0.9µM-100µM. MG132 was also dissolved in DMSO and was used at concentrations 
of 1µM or 10µM. Cells were harvested 4 hours after treatment. 
2.3 Whole plasmid mutagenesis 
Phosphorylation sites were identified by locating serine and threonine residues as well 
as the putative destruction box in the N-terminal region (denoted by the classic 
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sequence RXXL). Primers were then designed containing the intended mutations to 
each of these sites. Substitution mutations were introduced such that the new residue 
became an aspartate for the phosphomimetic mutants and alanine for all other 





C. Primers were synthesised by Eurofins MWG Genomics. 
Primers were received and dissolved in nuclease-free water to obtain a concentration 
of 100µM. To perform PCR of plasmids >10kb, 0.4µM of forward and reverse 
primers is required according to the protocol provided by Agilent Technologies for the 
PfuUltra II Hotstart 2x PCR Master Mix. Briefly, reactions occurred in a mixture 
containing 0.4µM each of the complementary forward and reverse primers, 20ng of 
template DNA (WT Ciz1) and a final 1x concentration of Master Mix. The rest of the 
volume was made up with nuclease-free water. This was prepared in PCR tubes. 
Samples were then placed in the PCR machine (Techne TC-312; Jencons-PLS) and 
run at the appropriate program (Table 1). Following PCR, plasmids were subjected to 
digestion with DpnI. 
2.4 Preparation of an agarose gel 
The 0.7% agarose gel was prepared by using powdered agarose with low 
electroendosmosis (EEO) and 1x Tris/Borate/EDTA (TBE) buffer. This mixture was 
heated until all the agarose had been dissolved before addition of ethidium bromide 
1 1 cycle 92
o
C 2 minutes 
2 30 cycles 92
o
C 20 seconds 
  Primer Tm- 5
o
C 20 seconds 
  68
o
C 30 seconds/kb 
3 1 cycle 68
o
C 5 minutes 





when the solution had cooled to ~50
o
C. This mixture was then added to the gel tank 
and left to set. 
2.5 Confirming success of PCR 
To confirm the PCR had been successful, samples were subjected to agarose gel 
electrophoresis. A 0.7% gel was prepared (section 2.4) and loaded with an equal 
mixture of plasmid and 6x Gel Loading Dye (BioLabs) with a 1kb ladder (BioLabs) 
for reference. The DNA was separated by electrophoresis at 100V for one hour. The 
gel was imaged using the Bio-RAD ChemiDoc
TM
 MP System and the accompanying 
Image Lab
TM
 4.1 Software. 
2.6 Preparing competent Top 10 E. coli 
Competent E. coli cells were prepared by inoculating 5ml of LB medium with 1µl of 
Top 10 E.coli cells which were left to grow overnight at 37
o
C at 150rpm. 750µl of the 
E. coli was used to inoculate 75ml of fresh LB medium, incubated for approximately 
two hours until the OD600 was between 0.3 and 0.6. At this point, the broth was 
centrifuged at 3000g for 10 minutes at 4
o
C after which the medium was removed. The 
pellet was resuspended in 30ml ice cold CCMB80 buffer prepared on the day and left 
to incubate for 20 minutes on ice following another round of centrifugation. The pellet 
was resuspended in 4ml of ice cold CCMB80 buffer before being placed in cooled 
eppendorfs in 200µl aliquots. These were frozen at -80
o
C. 







2.7 Preparation of E. coli for plasmid isolation and DNA sequencing 
To confirm introduction of each mutation had been successful for the phosphomimetic 
mutants and D-box mutant, competent Top 10 Escherichia coli were transformed with 
the mutated plasmids. Transformation was performed by adding 1µl of plasmid to 
competent cells and incubated for 30 minutes on ice, 1 minute at 42
o
C then another 5 
minutes on ice before being left on a shaker at 37
o
C for 1 hour following addition of 
500µl of SOC medium (Super Optimal broth with Catabolite repression, Thermo 
Fisher Scirntific) to maximise transformation efficiency. This was plated onto LB agar 




A single colony was used to inoculate 5ml of LB medium supplemented with 
kanamycin (50µg/ml) which was incubated at 37
o
C and 150rpm for a maximum of 16 
hours. This was followed by DNA extraction according to the protocol provided either 
with the QIAprep
®
 Spin Miniprep Kit or GeneJET Plasmid Miniprep Kit (Thermo 
Scientific). DNA samples were then sent to Eurofins MWG Genomics at 50-100µg/ml 
for sequencing and presence of the correct mutations was verified. 
For pGEX-6P3 plasmids, BL-21 (DE3) E. coli cells were used for transformation. The 
LB agar and LB medium were supplemented with ampicillin (100µg/ml). 
Escherichia coli strain Genotype 
Competent Top 10  F–mcrA Δ(mrr-hsdRMS-
mcrBC)Φ80lacZΔM15ΔlacX74recA1araD139Δ(ara 
leu)7697galU galK rpsL (StrR) endA1 nupG (Inviitrogen) 
BL-21 (DE3) fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS 
λ DE3 = λ sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T7 
gene1) i21 ∆nin5 (BioLabs) 
Table 2: E. coli strains and their genotypes used in these experiments 
34 
 
2.8 Transfection of mouse fibroblasts 
For asynchronous cell experiments; when confluency of cells reached over 70%, cells 
were trypsinised as described previously, cells placed in 5-10ml DMEM.  Cells were 
harvested by centrifugation at 500g for 5 minutes to form a pellet. This pellet was 
resuspended in 100µl Nucleofector
®
 Solution with Nucleofector
®
 Supplement added 
before 5µl of plasmid or siRNA was added. This mixture was placed in a cuvette 
which in turn was placed in the Lonza Nucleofector
TM
 2b Device with the appropriate 
program selected for cell type (Program 30 – NIH-3T3). Following this process, living 
cells were then plated out in supplemented DMEM (10% FBS and 1x penicillin-
streptomycine-glutamine) and incubated for 12-24 hours at 37
o
C in 5% CO2. 
For synchronous cell experiments; cells were transfected as described (section 2.2). 
One 15cm diameter plate was used for two transfections. 
2.9 Scrape harvesting cells for protein isolation 
After appropriate incubation periods (16-24hrs post-transfection, 4hrs post-drug 
treatments), cells were harvested using Cytoskeleton Buffer (CSK) supplemented with 
a protease inhibitor tablet and 1mM Dithiothreitol (DTT) in order to remove a large 
proportion of proteins not bound to the scaffold or the chromatin. Once harvested, 
phenylmethanesulfonylfluoride (PMSF), a serine protease inhibitor was added to the 
cell mixture at a final concentration of 2mM. This constituted the total protein 
fraction. Half of this fraction was removed and 1% Triton X-100 was added before the 
sample was spun at 14 000g for 5 minutes. The supernatant represents the detergent 
soluble fraction and the pellet contains the chromatin fraction. Each of the three 
fractions was placed in equal volumes of a 4x SDS-PAGE loading buffer 
supplemented with DTT at a final concentration of 200mM before being boiled for 10 
minutes. Samples were stored at -20
o
C until use. 
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o CSK buffer composition: 10mM PIPES pH6.8 
 300mM Sucrose  
 100mM Sodium chloride 
 3mM Magnesium chloride 
  
o 4x SDS-PAGE loading buffer composition: 240mM Tris-HCl pH 6.8 
 8% SDS 
 40% Glycerol 
 Pinch of Bromophenol Blue 
2.10 Determination of the proportion of cells in the S phase by 5-ethynyl-2’-
deoxyuridine (EdU) incorporation 
Synchronisation of cells (section 2.2) was confirmed using EdU labelling (EdU Click-
iT method - Invitrogen) of cells grown on coverslips. Time points occurred 16-24 
hours post-transfection at 2 hour intervals after release from quiescence. At 15.5 hours 
post-release from quiescence, coverslips with cells were placed individually into a 24-
well plate containing 1ml media. Addition of 2µM EdU occurred 30 minutes prior to 
the first time point. After labelling with EdU, coverslips were removed from media 
and washed twice with PBS before fixing with 4% PFA for 15 minutes. Coverslips 
were then washed with 3% BSA in PBS twice followed by incubation with 0.5% 
Triton X-100 for 20 minutes at room temperature. After washing with 3% BSA in 
PBS twice again, EdU Click-iT cocktail was added to each coverslip so that the 
surface was completely covered (as described in manufacturer’s instructions). This 
was incubated for 30 minutes in the dark. Prior to mounting on slides using mounting 
medium + DAPI, coverslips were washed again three times with 3% BSA in PBS, 
then twice again in PBS. For each coverslip, 100 nuclei were scored and the 
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percentage of cells in S phase was calculated by determining the number of EdU 
positive nuclei.  
2.11 Isolating RNA from synchronised cell populations for qPCR analysis 
Cells were trypsinised as described (section 2.2). Following trypsinisation, cells were 
centrifuged at 500g for minutes to form a pellet, which was then frozen at -80
o
C.  
RNA extraction was performed using the PureLink
TM
 RNA Mini Kit (ambion by life 
technologies) according to manufacturer’s instructions. Briefly, fresh lysis buffer was 
prepared by adding 1% v/v 2-mercaptoethanol. The pellet was thawed and 0.6ml lysis 
buffer was added. This mixture was vortexed in order to lyse the cells. 
Homogenisation was performed at room temperature by passing the lysate through an 
18-21 gauge syringe needle 5-10 times. All other steps occurred on ice. To each 
volume of cell homogenate, 0.6ml of 70% ethanol was added followed by vortexing to 
mix. The sample was then placed in a spin column and centrifuged at 12 000g for 15 
seconds at room temperature. The flow-through was discarded. 700µl Wash Buffer I 
was added twice to the spin cartridge and centrifuged as before; followed by two 
washes with Wash Buffer II. An extra centrifugation step was performed in order to 
dry the membrane before adding 30-100µl RNase free water to the centre of the spin 
cartridge. This was incubated at room temperature for 1 minute followed by 
centrifugation at 2000g for 2 minutes to elute the RNA from the membrane. Purified 
RNA was stored at -80
o
C. 
2.12 Determining mRNA levels by real time quantitative PCR  
RNA extractions for transcript level analyses by qPCR were prepared using an 
EXPRESS One-Step SuperScript® qRT-PCR Kit with Premixed ROX (Invitrogen). 
Each reaction required 20µl master mix containing both the sample and the primers. 
For every 20µl, half the volume consisted of EXPRESS qPCR SuperMix with 
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Premixed ROX. 2µl EXPRESS SuperScript
®
 Mix for One-Step qPCR and equal 
concentrations of template RNA were added. The rest of the volume was made up by 
DEPC-treated water. To each well of the PCR plate, 19.6µl of master mix was added 
before 0.4µl of the fluorescent primer mix was added. The 96-well PCR plate was 
then placed in the qRT-PCR machine with the correct program selected. GAPDH was 
used as the reference. The cycle threshold (Ct) was determined as the number of PCR 
cycles required to reach the detectable threshold of fluorescence emitted by PCR 
products, which occurs during the exponential phase of the reaction. The Ct value is 
inversely proportionate to the original amount of transcript. 
1 50
o
C 15 minutes 
2 95
o
C 2 minutes 
3 40 cycles 95
o
C 15 seconds 
60
o
C 1 minute 
Table 3: Conditions required for qPCR to determine RNA levels  
2.13 Subcellular fractionation isolating chromatin, high salt resistant and nuclear 
matrix fractions 
The method described here is a modified version of that used by Ainscough et al. 
(2007). Cells were harvested as described (section 2.9) before 1% Triton X-100 was 
added. An aliquot of this mixture was removed, forming the total protein fraction. The 
remaining mixture was centrifuged at 10 000g for 5 minutes; the supernatant 
containing the detergent soluble fraction. The high salt soluble fraction was prepared 
by resuspending the pellet in high salt CSK buffer (CSK + 0.5M NaCl). Following 
centrifugation at 10000g for 5 minutes, the supernatant was removed. The pellet was 
then washed 3 times with 1x DNase I buffer to reduce salt concentration prior to 
DNase I digestion (diluted 1:10 in 1x DNase I buffer – Thermo Fisher Scientific) was 
added; followed by an hour incubation period at room temperature. After 
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centrifugation at 17 000g for 5 minutes, the supernatant was placed in a fresh 
Eppendorf (Dnase supernatant). This was followed by repeating incubation with high 
salt CSK to remove the digested DNA, making up the DNA-free fraction following 
centrifugation. The pellet was resuspended in 4x SDS-PAGE loading buffer. An 
incubation period of 5 minutes occurred prior to each centrifugation step unless stated 
otherwise. All steps were performed on ice unless indicated. 
o DNase I buffer composition: 100mM Tris-HCl pH 7.5 
 25mM Magnesium chloride 
 1mM Calcium chloride 
2.14 SDS-PAGE gel electrophoresis 
Samples were boiled at 95
o
C for 10 minutes prior to loading in Mini-PROTEAN
®
 
Precast Gels (BIO-RAD). Gels were placed in a Mini-PROTEAN
®
 Vertical 
Electrophoresis Cell (BIO-RAD) containing 1x Tris-Glycine-SDS PAGE Buffer 
(National Diagnostics) and samples were loaded. Proteins were separated by 
electrophoresis for approximately 30 minutes at 200V. 
2.15 Western blots 
Semi-dry western blots were prepared by incubation of Mini-PROTEAN
®
 Precast 
Gels (BIO-RAD) in transfer buffer for 5 minutes and sandwiching between 4 pieces of 
filter paper saturated in transfer buffer, nitrocellulose 0.4µm membrane (GE 
Healthcare Life Sciences), gel and 4 more pieces of filter paper. Proteins were 
transferred by semi-dry blotting at 0.8mAmp/cm
2
 (typically 63mA per blot) for 1.5-2 
hours. Blots were then blocked for a minimum of 30 minutes with TBST+1% w/v 
BSA (Tris-Buffered Saline + Tween-20 and Bovine Serum Albumin) or 5% milk 
powder in TBST before the primary antibody was added at the appropriate dilution. 
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This was incubated for 1-2 hours at room temperature or overnight at 4
o
C. Washing 
with TBST+BSA was performed four times for 5 minutes each before adding the 
appropriate secondary antibody at a dilution of 1:5000. Following an incubation 
period of one hour, washing was performed as before, this time using TBST. Peroxide 
solution and luminol enhancer solution (Cynagen Westar ƞC) were mixed together 
(1:1 ratio), then placed on the blot after positioning in the BIO-RAD ChemiDoc
TM
 MP 
System. The blots were then developed. The blots were first probed with α-actin and 
actin was quantified using the Image Lab
TM
 4.1 Software to ensure loading of samples 
was equal for most cell samples. Ciz1 levels were quantified relative to actin 
quantification levels. 
Antibody Dilution Antigen Secondary antibody  
(+HRP) (1:5000) 
α-β actin  1:2000 β-actin α-mouse  
α-N471 1:500 Ciz1 α-rabbit  
α-pT293 1:200 pT293 in Ciz1 α-rabbit 
α-pS331 1:200 pS331 in Ciz1 α-rabbit 
α-cyclin A 1:500 Cyclin A α-mouse 
α-cyclin E 1:1000 Cyclin E α-rabbit 
α-HA HRP 1:1000 Haemaglutinin N/A 
Table 4: Primary and secondary antibodies used to probe western blots 
pIMAGO-biotin Phosphoprotein Detection (Expedeon) 
Labelling reactions were performed according to manufacturer’s instructions 
(Expedeon). Briefly, samples were boiled and allowed to cool down before adding 1x 
IAA solution. Samples were incubated for 15 minutes before being loaded onto a gel.  
When transferring to the nitrocellulose membrane, a second piece of membrane was 
placed before the gel as well in order to bind any contaminants, thus reducing 
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nonspecific background signal later on. The rest of the transfer process occurred as 
normal. The membrane was the blocked for 1 hour with 1x Blocking buffer. A 1:1000 
mixture of pIMAGO reagent in 1x pIMAGO buffer was prepared before adding to the 
membrane followed by another 1 hour incubation. The membrane was washed three 
times with 1x Wash buffer and once with TBST. A 1:1000 mixture of avidin-HRP in 
1x blocking buffer was prepared before adding to the membrane and incubating for 1 
hour. The membrane was washed three times with TBST and a signal was obtained as 
before except Cynagen Westar Supernova enhanced chemiluminescence solution was 
used instead. 
o Transfer Buffer (200ml): 7.2g Trizma base 
 0.44g CAPS 
 20ml 100% ethanol 
 0.4ml 10% w/v SDS 
2.16 Immunofluorescence 
Success of transfection and confirmation of the location of ECiz1 were determined 
using immunofluorescence as the plasmid containing Ciz1 also contains a GFP (Green 
Fluorescent Protein) tag. Slides were prepared by growing transfected cells on 
coverslips. These coverslips were then washed twice with CSK before being placed in 
a 24 well plate. For the total protein fraction, cells were fixed using 4% PFA 
(Paraformaldehyde). The following treatments were all performed on ice. For the 
detergent resistant fraction, cells were treated with 1% Triton X-100 in CSK for 5 
minutes, followed by fixing with 4% PFA. The high salt resistant fraction was formed 
by adding high salt CSK as used previously for 5 minutes before being fixed. The 
remaining nuclear matrix was prepared by washing first with DNaseI buffer before 
incubating with DNaseI (diluted 1:10 in 1x DNaseI buffer) at room temperature for 
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one hour. This was followed by washing with high salt CSK and fixing. Once fixing 
with 4% PFA was complete, coverslips were washed with PBS (Phosphate Buffered 
Saline). For each coverslip, a drop of VECTASHIELD
®
 Mounting Medium with 
DAPI (Vector Laboratories) was placed on a microscope slide before placing the dried 
coverslip on top. A LSM510 laser scanning confocal microscope was used for 
viewing these treated cells and images taken along with the accompanying software. 
2.17 Immunoprecipitation 
Mouse fibroblasts (D3T3) were transfected with GFP-Ciz1 constructs and HA-
Ubiquitin (HA-Ub) 24 hours before commencing this procedure. At the time of 
harvesting, cells had reached ~80% confluency. Cells were harvested using lysis 
buffer and had 1% v/v Triton X-100 added before being left to incubate on ice for 5 
minutes. This was followed by centrifugation at 13000g to extract the Ciz1 protein. 
The supernatant containing the protein had 3x v/v binding buffer added prior to 
addition of 4x SDS-PAGE buffer followed by boiling for 10 minutes. These samples 
were used to confirm the presence of Ciz1 within the supernatant. Following this step, 
5µl of 2-10µg of affinity-purified α-N471 was added to each sample. Control samples 
had no antibody added. Samples were then incubated for a minimum of 2 hours in 
order to form the immune complex. 
The Pierce
®
 Classic IP kit (Thermo Scientific) was used for these experiments. Pierce 
Protein A/G Agarose was placed into a Pierce Spin Column and spun down to leave 
only the resin. This was then washed twice with ice-cold binding buffer before 
addition of the antibody/lysate sample and incubation with gentle end-over-end 
mixing for 1 hour. Following centrifugation, the flow-through was saved until the IP 
was confirmed as successful. The resin was then washed three times with binding 
buffer before 50µl of 4x SDS-PAGE loading buffer was added and the samples boiled 
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for 10 minutes. Finally, samples were then centrifuged for 1 minute at 1000g and the 
flow-through was used to perform western blots. Each western blot was duplicated 
with separate gels probed with α-N471 and α-HA HRP respectively. 
o Lysis buffer (50ml): 1x Phosphate Buffered Saline 
 1x Complete Protease Inhibitors (Roche) 
 1mM DTT 
o Binding/Wash buffer (50ml): 50mM HEPES pH 7.8 
 10mM Magnesium chloride 
 20mM Calcium chloride 
 130mM Potassium chloride 
 0.02% Triton X-100 
 1mM DTT 
 1x Complete Protease Inhibitors (Roche) 
2.18 Ni
2+
-NTA immobilisation of His-Ub 
Cells were transfected with His-Ub 24 hours prior to harvesting. Cells were then 
washed with ice cold lysis buffer (PBS, 100mM NaCl, 1mM DTT, 10mM Imidazole, 
1x protease inhibitor tablet) followed by incubation for 5 minutes on ice in lysis 
buffer. Cells were then scrape harvested and made up to a volume of 200µl with lysis 
buffer to which 100µM PMSF and 0.5% Triton X-100 were added. Following 
incubation on ice for 5 minutes, samples were centrifuged at 10 000g for 5 minutes. 
The supernatant contained the low salt extract. The pellet was then resuspended in in 
200µl high salt buffer (lysis buffer + final concentration of 500mM NaCl). This was 
centrifuged again at 17 000g for 5 minutes, with the supernatant containing the high 
salt extract. IP spin columns were prepared with 30µl Ni
2+
-NTA resin for each 
reaction. These were washed three times with lysis buffer prior to addition of cell 
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lysates. The final volume of each sample as made up to 400µl with lysis buffer and an 
aliquot was removed from each sample to confirm presence of the protein of interest 
prior to immobilisation. The cell lysates were then added to the resin and allowed to 
bind for 1 hour on a mixer at 4
o
C. This was followed by washing four times with lysis 
buffer before addition of 4x SDS-PAGE loading buffer and boiling for 10 minutes. 
The denatured protein was then collected by centrifugation. 
2.19 Preparation of autoinduction media 
For each recombinant protein, 750ml ZY was prepared. This contained 7.5g Tryptone 
(BD Biosciences) and 3.75g Yeast extract (Fisher Scientific). A 20x stock 
concentration of NPS was prepared with 0.5M ammonium sulphate, 1M potassium 
phosphate monobasic and 1M sodium phosphate dibasic. A 50x stock concentration of 
5052 was prepared containing 25% glycerol, 0.139M glucose (Fisher Scientific) and 
0.278M α-lactose monohydrate. These mixtures were then autoclaved for 15 minutes 
at 121
o
C. Magnesium sulphate and 1000x trace metals mixtures were filter sterilised. 
o 1000x trace 
metals (100ml): 
Metal (volume) 1x concentration 
 0.1M FeCl3.6H2O (50ml) 50µM Fe 
 1M CaCl2 (2ml) 20µM Ca 
 1M MnCl2.4H2O (1ml) 10µM Mn 
 1M ZnSO4.7H2O (1ml) 10µM Zn 
 0.2M CoCl2.6H2O (1ml) 2µM Co 
 0.1M CuCl2.2H2O (2ml) 2µM Cu 
 0.2M NiCl2.6H2O (1ml) 2µM Ni 
 0.1M Na2MoO4.2H2O (2ml) 2µM Mo 
44 
 
 0.1M Na2SeO3.5H2O (2ml) 2µM Se 
 0.1M H3BO3 (2ml) 2µM H3BO3 
2.20 Over-expression of recombinant protein using autoinduction in E. coli  
Autoinduction was used to produce the proteins of interest. BL-21 E. coli were 
transformed with pGEX-6P3 plasmids containing various protein constructs using the 
same protocol as that used for the transformation of Top 10 E. coli with ampicillin 
(1:1000) used instead of kanamycin. Following growth on LB agar, a single colony 
was used to inoculate 5 ml of LB supplemented with ampicillin (100µg/ml) and 
incubated overnight at 37
o
C, shaking at 200rpm; followed by inoculation of 75ml of 
LB and ampicillin for another night. This culture was then added to 750ml of a 
mixture of ZY, 1mM MgSO4, 1x 5052, 1x NPS, 100µg/ml ampicillin and 1:1000 
dilution of trace metals. This mixture was incubated at 20
o
C for 24 hours, shaking at 
150rpm. The culture was then centrifuged for 15 minutes at 4500g and the majority of 
the supernatant removed followed by centrifugation at 3000g for 15 minutes. The 
remaining pellet was stored at -80
o
C.  
The pellet was resuspended in 25ml HEPES buffered saline (HBS – 10mM HEPES 
pH7.8, 135mM NaCl, 1mM EDTA) supplemented with DTT and one protease 
inhibitor tablet. Once the pellet had been resuspended, the cells were sonicated at 
maximum power for 15 seconds 5 times with a one minute rest between sonication. 
The cell mixture was then placed in a sorval tube and spun at 20 000g for 30 minutes 
at 4
o
C in a JA 25.5 rotor. During centrifugation, 0.75ml of Glutathione Sepharose
TM
 
4B beads (GE Healthcare) were placed in 50ml bead wash buffer (HBS+DTT) and left 
on a roller for a minimum of one hour to rehydrate them. Subsequently, the wash 
buffer was removed from the beads and the cell lysate was placed on them. To allow 





mixture was then centrifuged at 1000g for 1 minute and the supernatant removed, with 
a 20µl aliquot removed to show purification levels at each wash stage. The beads were 
washed five times with 10ml of wash buffer (HBS  + 1x protease inhibitor tablet + 
DTT), followed by centrifugation at 1000g for 1 minute after being placed on ice for a 
few minutes. After each centrifugation, an aliquot was removed.  
2.21 Protein interaction studies 
To cleave the beads from the protein, the mixture was washed 3 times with 3C 
cleavage buffer (50mM TrisHCl pH 7.35, 15mM NaCl) in the same manner as above. 
10µl of 3C PreScission
TM
 Protease (GE Healthcare) was then added to the mixture in 
a 1.5ml eppendorf with about 200µl head-space to avoid shearing of the protein due to 
mechanical stress. This was then left on a wheel at 4
o
C overnight. 
To elute the protein, the mixture was placed in a spin column and spun at 1000g for 1 
minute. The flow-through containing the protein was aliquoted and stored at -80
o
C. A 
smaller aliquot was used for purification identification and the beads were 
resuspended in 3C cleavage buffer so an aliquot could be removed for this purpose as 
well. These samples were mixed with 4x SDS-PAGE loading buffer + DTT and run 
on a gel. This was stained with InstantBlue
TM
 (Coomassie Based Staining Solution) 
for an hour, then imaged. To prove the presence of the protein of interest, a western 
blot was also performed. 
For protein-protein binding studies, one protein cleaved from the glutathione 
sepharose beads was added to another protein still bound to these beads. The mixture 
was placed in a 1.5ml eppendorf and an aliquot removed for a sample before binding. 
3C buffer was added with about 200µl head space. The eppendorfs were placed on a 
wheel and left to bind for an hour at 4
o
C. The beads were then washed three times 
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with 3C buffer as described previously before adding 4x SDS-PAGE loading buffer 
and boiling for ten minutes.  
2.22 Determining protein concentration 
Protein concentrations following purification were determined using a Pierce
®
 BCA 
Protein Assay Kit as per manufacturer’s instructions (Thermo Scientific). The 
standard curve was produced using an albumin standard (bovine serum albumin) at 
2mg.ml diluted in 3C cleavage buffer, containing 1mM DTT. Compatibility Reagent 
Stock Solution was added at an equal volume to each standard and sample and 
allowed to incubate at 37
o
C for 15 minutes to degrade DTT. The BCA Working 
Reagent containing Cu
2+
 was then added followed by further incubation at 37
o
C for 30 
minutes. Absorbance of each standard and sample was read at 562nm.  
2.23 In vitro kinase assays to determine phosphorylation kinetics of Ciz1 by 
cyclin A-CDK2 
These reactions were performed under pseudo-first order reaction conditions in a 
buffer containing 50mM HEPES pH 7.8, 20mM MgCl2, 10mM ATP and 1mM DTT. 
In the initial experiments, 50nM cyclin A-CDK2 and 1µM Ciz1 were used. Later 
experiments were performed with 5nM cyclin A-CDK2 and Ciz1 concentrations 
between 50nM-2µM. Each reaction had a total buffer volume of 200µl contained in a 
1.5ml eppendorf before the correct volume of Ciz1 was added. The eppendorf was 
then placed in heat block at 37
o
C. At t=0, the appropriate volume of cyclin A-CDK2 
was added and an aliquot of 25µl immediately removed. Further aliquots were 
removed at appropriate time points. Removed aliquots were mixed with an equal 

















3.1 REGULATION OF CIZ1 STABILITY BY CYCLIN DEPENDENT 
KINASE-MEDIATED PHOSPHORYLATION 
3.1.1 Identification of phosphorylation sites responsible for protein stability 
Since the data presented previously in Figure 5 suggests that Ciz1 is stabilised when 
phosphorylated by CDK, it was decided to investigate which sites within the protein 
are phosphorylated that are responsible for this stabilisation. ECiz1 (embryonic Ciz1) 
has fourteen phosphorylation sites as illustrated in Figure 6, half of which are 
contained within the active-replication fragment Ciz1-N471 as identified by Copeland 
et al. (2010b).  One method of testing each individual putative CDK-phosphorylation 
site is using phosphomimetic mutants of Ciz1. 
Phosphomimetic mutants have an acidic residue that is introduced at putative CDK-
phosphorylation sites that mimic the negative charge introduced by phosphorylation at 
these sites. Analyses of such mutants have been used in many studies to investigate 
the role of phosphorylation in protein function. Aspartate as a phosphomimetic amino 
acid and alanine as a non-phosphorylatable amino acid are commonly used (Lamia et 
al., 2009, Gu et al., 2009, Copeland et al., 2015). Using these phosphomimetic 
mutants, the aim was to determine whether Ciz1 could be stabilised; that is protected 
from poly-ubiquitylation and proteasomal degradation after inhibition of CDK 
activity. Mutant Ciz1 proteins could be assayed after addition of a CDK inhibitor in 
the presence and absence of a proteasomal inhibitor in order to identify which, if any, 
sites contributed to protein stability. If phosphorylation of a certain site does 
contribute to protein stability, inhibition of CDK activity should not have any, or have 
little, effect on protein levels as opposed to decreased protein levels when that site is 
not phosphorylated. These phosphomimetic mutants would be created by designing 
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primers followed by whole plasmid mutagenesis by PCR to introduce the desired 
mutations followed by DNA sequencing (Eurofins Genomics) to verify the presence 
of these mutations. 
No 3D structure of Ciz1 has been determined yet so establishing which of these 
putative CDK-phosphorylation sites are the most likely candidates for being 
phosphorylated by CDKs and increasing protein stability by observing whether sites 
are easily accessible to CDKs in the first place is not possible. However, previous 
studies have revealed four sites that are phosphorylated by CDKs: T144, T192, T293 
and S331 (Copeland et al., 2015). Functions of these phosphorylation events have 
been established for the first three sites but not the fourth. It is therefore possible that 
phosphorylation of S331 could lead to increased protein stability. A putative 
destruction box, denoted by the sequence ‘RXXL’ was also identified. Therefore, 
putative CDK-phosphorylation sites situated closest to the D-box in the primary 
sequence are also of particular interest as it is possible that if these sites are 
phosphorylated, a physical block could be put into place as a consequence such that an 
E3 ligase could not actually bind to the D-box, thus preventing ubiquitylation from 
occurring. 
Several proteomic analyses of post-translational modifications have revealed other 
phosphorylated sites within Ciz1 in several species including humans and mice 
(Sharma et al., 2014, Mertins et al., 2013). Identification of these sites within ECiz1 
that are equivalent to those in Ciz1 in other species as well as humans would also be 





Figure 6: Identification of putative CDK phosphorylation sites and creation of 
phosphomimetic mutants 
Diagram of the full-length Ciz1 protein and location of each putative CDK 
phosphorylation site identified for the creation of the phosphomimetic mutants.  
 
3.1.2 Optimising conditions and drug concentrations for Ciz1-phosphomimetic 
mutant stability assays 
In order to use these phosphomimetic mutants, an assay first needed to be set up that 
would allow conditions to be changed in an attempt to destabilise the Ciz1 protein. All 
experiments using Ciz1 constructs were ECiz1 forms and were set up such that both 
endogenous Ciz1 protein and transfected GFP-Ciz1 constructs were tested. Cells were 
harvested four hours post-drug treatments and, if transfected, 16-24 hours post-
transfection. A range of drug concentrations were used. The CDK inhibitor 
roscovitine was used at final concentrations between 0.9µM and 100µM whereas the 
proteasomal inhibitor MG132 was used at a final concentration of either 1µM or 




Figure 7: Treating cells with 0.9µM-3.6µM Roscovitine and 1µM MG132. 
Cells were treated with 0.9-3.6uM roscovitine and 1uM MG132 as indicated. Cells 
were harvested four hours post-drug treatments and samples were used to perform 
western blots. Total protein fractions were used. (A) Western blot showing 
endogenous Ciz1 levels following drug treatments. Actin was used as a loading 
control. (B) Densitometry of the bands shown in (A) was performed in order to 
quantify Ciz1 levels. The histogram shows Ciz1 levels when quantified relative to 
actin. 
Roscovitine is generally used at concentrations between 10µM and 50µM (Alessi et 
al., 1998, Planchais et al., 1997, Kang et al., 2011, Hahntow et al., 2004). Roscovitine 
is mainly used to observe effects of inhibiting CDK1/2 phosphorylation; although a 
study into roscovitine itself revealed that this drug is only effective against certain 
kinases and to varying degrees (Bach et al., 2005). A study performed by Meijer et al. 
(1997) revealed that roscovitine inhibits cyclin E-CDK2 and cyclin A-CDK2; with 
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however, inhibit cyclin D-CDK4/6. However, since lower and higher drug 
concentrations have also been used, a range of concentrations were tested.  
The lowest concentrations tested started with a concentration of 0.9µM (Fig. 7), with 
1.8µM and 3.6µM also tested to observe whether any effects that occurred were 
concentration-dependent. The western blot showing drug effects on endogenous Ciz1 
(Fig. 7A) indicates no significant change in protein levels as would be expected when 
compared to previous results presented in Figure 5. The accompanying histogram 
shows that although Ciz1 levels are not constant, changes do occur. However, as can 
be seen in Figure 7B, at 0.9µM (lane 2), endogenous Ciz1 levels appear to increase 
relative to the controls whereas the higher concentrations (lanes 3 and 4) do cause 
Ciz1 levels to decrease, with a slight recovery with addition of MG132 (lane 5), 
although this is not immediately evident in the western blot (Fig. 7A).  
It was reasoned that if the correct conditions could be determined in order to test the 
stability of each of the fourteen phosphomimetic mutants, drug concentrations 
required would need to be ideal for affecting transfected Ciz1 protein levels. As small 
changes in endogenous protein expression were observed when cells were treated with 
1.8uM and 3.6uM roscovitine, similar changes in exogenous Ciz1 protein expression 
were expected to be observed at slightly higher drug concentrations. This was 
determined by taking into account not only higher levels of the protein of interest after 
transfection of cells with the Ciz1 construct, but also the desire to observe a greater 
change in protein expression, if indeed one was present. The following concentrations 
of roscovitine tested therefore were 9.9µM, 19.7µM and 39.5µM on cells transfected 
with WT-GFP-Ciz1. However, no visible difference is seen in GFP-WT-Ciz1 protein 
levels in the western blot (Fig. 8A) and quantifications again show that GFP-WT-Ciz1 
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levels are not altered as expected, instead appearing to increase slightly at higher drug 
concentrations (lanes 3 and 4, Fig. 8B).  
  
Figure 8: Treating cells with 9.9µM-39.5µM Roscovitine and 10µM MG132. 
Cells were transfected with WT-GFP-Ciz1 twenty hours prior to drug treatments and 
were treated with 9.9-39.5uM roscovitine and 10uM MG132 as indicated. Cells were 
harvested four hours post-drug treatments and total protein fractions were used to 
perform western blots. (A) Western blot showing transfected GFP-WT-Ciz1 levels 
following drug treatments. Actin was used as a loading control. (B) Densitometry of 
the bands shown in (A) was performed in order to quantify Ciz1 levels. The histogram 
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Figure 9: Treating cells with 15µM-60µM Roscovitine and 1µM MG132. 
Cells were transfected with WT-GFP-Ciz1 and treated twenty hours later with 15-
60uM roscovitine and 1uM MG132 as indicated. Cells were harvested four hours 
post-drug treatments and total protein fractions were used to perform western blots. 
Actin was used as a loading control. (A) Western blot showing transfected GFP-WT-
Ciz1 levels following drug treatments. (B) The histogram of Ciz1 protein levels 
according to the western blot shown in (A). (C) Western blot showing transfected 
GFP-WT-Ciz1 levels following drug treatments. (D) The histogram of Ciz1 protein 
levels according to the western blot shown in (C). 
The next highest concentrations of roscovitine tested were 15µM, 30µM and 60µM. 
The first time this experiment was performed, protein levels in the control sample 
were too low to detect. However, the western blot (Fig. 9A) did show visibly altered 
GFP-WT-Ciz1 protein levels as expected, which was confirmed following 
quantification (Fig. 9B). Unfortunately, when this experiment was repeated (Figs. 9C 
and D), GFP-WT-Ciz1 levels increased with addition of 30µM (lane 2) of roscovitine 
and continued to increase slightly with addition of MG132 (lane 3). This highlights 
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mutants requires a robust assay to determine the role for each phosphorylation site, 
which has not been achieved here with drug concentrations tested so far. 
The highest concentration of roscovitine tested was 100µM. Effects of treatment with  
roscovitine at this concentration on GFP-WT-Ciz1 levels are different when 
comparing the total (Figs. 10A and B) and chromatin (Figs. 10C and D) fractions. The 
western blots do not show any significant changes in Ciz1 levels and quantifications 
indicate that in the total protein fraction, Ciz1 levels increase with increasing 
concentrations of roscovitine (lanes 2 and 3) and increase further with addition of 
MG132 (lane 4) whereas with the chromatin fraction, Ciz1 levels do drop with the 
addition of 100µM roscovitine (lane 3) compared to control levels but addition of 
MG132 (lane 4) does not lead to much recovery of Ciz1.  
However, when observing GFP-Ciz1 levels in the presence of the proteasomal 
inhibitor MG132 in all experiments performed here, there appears to be a repeated 
increase of Ciz1 levels. This suggests that Ciz1 degradation is mediated by the 




Figure 10: Treating cells with 50µM-100µM Roscovitine and 10µM MG132: 
observing GFP-WT-Ciz1 
The accompanying histograms show quantified levels of Ciz1 protein relative to actin. 
(A) Western blot showing Ciz1 levels following drug treatments as indicated. This 
blot shows the total protein fraction. (B) The histogram of Ciz1 protein levels 
according to the western blot shown in (A). (C) Western blot showing Ciz1 levels 
following the same drug treatments as in (A). This blot shows the chromatin fraction. 
(D) The histogram of Ciz1 protein levels according to the western blot shown in (C).  
3.1.3 Observing effects of Cyclin A knockdown on Ciz1 protein stability  
Since it has also previously been shown that depletion of cyclin A affects Ciz1 protein 
levels in a manner similar to that of addition of a CDK inhibitor (Fig. 6) (Copeland, 
unpublished data); this approach was also tested in both synchronous (Fig. 11) and 
asynchronous populations of cells (Fig. 12). These experiments were performed as an 
attempt at an alternative method to chemiclly inhibiting CDK activity in order to 
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phosphorylate Ciz1 (Copeland et al., 2015); therefore by causing a depletion of cyclin 
A, phosphorylation of Ciz1 by this cyclin-CDK complex should no longer occur. Cells 
were synchronised (Fig. 11A) by contact inhibition and serum starvation for 48 hours, 
followed by release into the cell cycle once again, at which point transfection also 
occurred. Protein and RNA samples were harvested 24 hours post-release. 
 
Figure 11: Effects of Cyclin A knockdown on Ciz1 protein levels in a 
synchronised population of cells 
Western blots show levels of Ciz1 following cyclin A knockdown as indicated. 
MG132 was added at a final concentration of 10µM as indicated. Both proteins and 
RNA were harvested 24 hours post-transfection and four hours after drug-treatments. 
(A) Experimental design showing how cells are synchronised to G0 then re-entered 
into the cell cycle and transfected with α-ccna2 siRNA, followed by protein and RNA 
harvesting. (B) Cyclin A knockdown performed in a synchronised cell population; 
showing endogenous Ciz1 in the total protein fraction. (C) The chromatin fraction of 
the experiment shown in (A). (D) qPCR results showing levels of Cyclin A2.  
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As can be seen in Figure 11, cyclin A protein levels are significantly reduced in the 
synchronous cell populations. However, qPCR results show that levels of cyclin A2 
RNA are actually increased following transfection with α-ccna2 siRNA (Fig. 11D), 
and it appears that Ciz1 levels are not significantly affected (Figs. 11B and C). 
 
Figure 12: Effects of Cyclin A knockdown on Ciz1 protein levels in an 
asynchronous population of cells 
Western blots show levels of Ciz1 following cyclin A knockdown as indicated. 
MG132 was added at a final concentration of 10µM as indicated. Proteins were 
harvested 24 hours post-transfection and four hours after drug-treatments. (A) Cyclin 
A knockdown performed in an asynchronous cell population; showing both 
endogenous and transfected GFP-WT-Ciz1 levels in the total protein fraction as 
indicated. (B) This blot shows the chromatin fraction of the experiment outlined in 
(A). 
This can also be observed in the asynchronous cell populations (Figs. 12A and B) 
where GFP-WT-Ciz1 was co-transfected with the α-ccna2 siRNA. This experiment 
also revealed that inhibiton of the ubiquitin proteasome system did not affect Ciz1 
protein levels either. Endogenous Ciz1 protein was not detected in this experiment. 
The results presented in Figures 11 and 12 suggest that, contrary to previous data 
shown in Figure 5, absence of cyclin A does not affect Ciz1 protein stability. 
However, with an increase in cyclin A2 RNA levels in the synchronised cell 
population despite the decreased protein levels, it is possible that there was still 
enough cyclin A such that Ciz1 levels were not significantly affected. It is also 
important to note that the experimental results presented in Figure 11 requires 
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repeating due to a small sample size and a method of determining cell cycle status 
such as by EdU incorporation to determine S phase entry. 
3.1.4 Discussion 
Phosphorylation of certain proteins involved in regulating the cell cycle contributes to 
increased protein. This occurs due to the phosphorylation event preventing the specific 
E3 ligase from ubiquitylating its substrate, thus preventing it from being targeted by 
the 26S proteasome for degradation. This results in the levels of this protein being 
allowed to increase. Ciz1 has previously been shown to be phosphorylated at four 
distinct sites by cyclin A-CDK2. Phosphorylation of three of these sites leads to an 
inability of Ciz1 to bind cyclin A-CDK2; however a function of the phosphorylation 
event at the fourth site, S331, has not been attributed (Copeland et al., 2015). Since 
preliminary results shown in Figure 5 suggest that Ciz1 is degraded by the ubiquitin 
proteasome system (UPS), as evidenced by the fact that in the presence of the 26S 
proteasome chemical inhibitor MG132, Ciz1 protein levels are increased; and taking 
into account that many proteins degraded by this system are phosphorylated, causing 
them to be either marked for or protected from degradation (Mailand and Diffley, 
2005, Fukushima et al., 2013); further investigation was required in order to determine 
whether Ciz1 is indeed stabilised by phosphorylation and if so, which sites are 
responsible for this stabilisation. 
The identification of a putative destruction box within the primary sequence of Ciz1, 
found within many targets of the UPS, supported the preliminary findings shown in 
Figure 5 that suggested that Ciz1 is degraded by this system. Results presented here in 
Figures 7-10 further support this; as in the presence of a chemical inhibitor of the 26S 
proteasome MG132, Ciz1 levels consistently increase. Considering the fact that all 
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evidence presented to date shows that Ciz1 plays a role in regulating cell cycle 
progression (Coverley et al., 2005, Copeland et al., 2010a, Copeland et al., 2015), it 
seems logical that Ciz1 is itself partly regulated by the UPS as this system is largely 
responsible for the removal of other proteins involved in regulating the cell cycle at 
specific stages and is itself also tightly regulated (section 1.3). 
Results presented here also support the preliminary findings shown in Figure 5 with 
regards to a link between Ciz1 and CDK activity. Figure 7 reveals that in the presence 
of 1.8uM and 3.6uM roscovitine, a chemical inhibitor of CDK activity, Ciz1 levels 
drop when compared to the control (lanes 3 and 4 respectively). As Ciz1 has 
previously been shown to be phosphorylated by cyclin A-CDK2 (Copeland et al., 
2015) and inhibition of the proteasome results in a partial recovery of Ciz1 levels 
(lane 5, Figure 7), these results suggest that Ciz1 is phosphorylated by CDK activity 
and that this phosphorylation leads to increased protein stability. This observation, 
together with the identification of the putative destruction box, suggest that Ciz1 is a 
target of the APC/C E3 ligase since many other such targets also have a destruction 
box and phosphorylation at certain sites leads to increased protein stability (sections 
1.2 and 1.3). 
Having decided to create plasmids containing phosphomimetic mutants of Ciz1 in 
order to attempt to identify which site(s) within Ciz1 contribute(s) to increased protein 
stability when phosphorylated, it was unfortunate that in attempting to identify the 
correct conditions and drug concentrations required to destabilise the wild type form 
of the Ciz1 protein as previously observed (Fig. 5), a major problem was encountered. 
We were unable to reproduce the destabilisation of ectopically expressed GFP-Ciz1 
under a wide range of roscovitine concentrations (0.9µM-100µM). Most drug 
concentrations of roscovitine were tested at least twice in separate experiments. 
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Multiple sets of results for the same drug concentrations show that even under the 
same conditions, results obtained the second time sometimes showed what seemed to 
be the opposite of results obtained the first time the experiment was performed. The 
levels of recombinant Ciz1 protein found after transfection were considerably higher 
than the endogenous protein, which may have masked the effect of loss of Ciz1 levels. 
An inability to acquire reproducible results, whether or not they agreed with those 
previously observed (Fig. 5), led to a need to identify a different method that could be 
used to destabilise Ciz1 protein levels in order to study the effects of the 
phosphomimetic mutants on protein stability. Having previously observed that similar 
results were obtained following cyclin A knockdown, it was decided to attempt 
destabilisation using siRNAs instead of by chemical means since a possible 
explanation for not getting reproducible results is that the drugs used were causing 
side-effects previously not observed that led to the seemingly random changes in Ciz1 
protein levels at times. Sychronised cell experiments were used because there may be 
a cell cycle dependence for Ciz1 stability (Figs. 5A and C). 
Unfortunately, cyclin A knockdowns using α-ccna2 siRNA in both synchronous and 
asynchronous populations of cells also proved not to show the desired effects on Ciz1 
protein levels. However, this observation in the synchronised population of cells is 
slightly less clear as to the success of the cyclin A knockdown. This is because in the 
western blot (Figs. 11B and C), cyclin A protein levels have clearly decreased 
significantly. On the other hand, cyclin A transcript levels following qPCR suggest 
that cyclin A knockdown was not successful, which could explain why Ciz1 protein 
levels do not appear to have decreased as expected. The discrepancy between cyclin A 
transcript levels and cyclin A protein levels could be due to a number of factors. Since 
this experiment involved using a synchronised population of cells, a possible 
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explanation could be that cells were not properly synchronised, thus affecting protein 
levels and transcript levels differently. Considering that cyclin A knockdown was also 
performed in an asynchronous population of cells and cyclin A protein levels were 
successfully reduced but Ciz1 protein levels were unaffected, the failure to 
synchronise the cells is a possible explanation. Another possible explanation of course 
could be an experimental error, during the qPCR or preparation of the RNA samples, 
rather than analysis of the protein samples by western blot. To further analyse the 
reason behind the observed unaffected Ciz1 levels when cyclin A is knocked down in 
a synchronised population of cells, this experiment would have to be repeated and a 
method to observe cell cycle state, such as EdU labelling, would also have to be used. 
The lack of EdU labelling in this experiment makes the degree of synchronisation 
impossible to determine. Another attempt at performing a cyclin A knock-down and 
observing the effect on endogenous Ciz1 protein levels would also be performed. 
The inability to produce a method allowing the investigation of the role of 
phosphorylation of specific sites within Ciz1 to occur using phosphomimetic mutants 
as described meant that it was not possible to identify which site(s) within Ciz1 is/are 
phosphorylated by CDK activity leading to increased protein stability, as was planned. 









3.2 IDENTIFYING CIZ1 AS A TARGET OF THE UBIQUITIN 
PROTEASOME SYSTEM 
In section 3.1, treating cells with the chemical proteasome inhibitor MG132 
consistenly resulted in increased levels of Ciz1 protein as shown in western blots 
(Figs. 7-10 in the last lanes). These results supported the preliminary findings shown 
in Figure 5 (Copeland, unpublished data) and suggest that Ciz1 is degraded by the 
ubiquitin proteasome system (UPS). This suggestion is supported by the observation 
made also in section 3.1 that Ciz1 has a putative destruction box as part of its primary 
sequence. This sequence is frequently found in targets of one othe E3 ligases that 
forms part of this system. E3 ligases attach ubiquitin monomers to their targets as 
described in section 1.2, leading to the formation of poly-ubiquitin chains; thus 
targetting the substrate to the 26S proteasome for degradation. 
In order to determine whether or not Ciz1 is indeed a target of the UPS, it would first 
be useful to investigate if Ciz1 is poly-ubiquitylated. Multiple methods have been 
described to perform this determination including immunoprecipitation of the protein 
of interest after transfection with a plasmid containing ubiquitin and a tag such as 
haemaglutinin (HA) as well as transfection with a plasmid containing His-tagged 
ubiquitin followed by immobilisation with Ni
2+
-NTA. In the latter method, no 
immune complex is formed eliminating the need for antibodies at multiple stages and 
instead, simply when running samples for observation by western blot. In this case, 
the His tag binds directly to the Ni
2+
-NTA residue (Kirkpatrick et al., 2005) whereas 
in immunoprecipitation experiments, proteins bind to the protein A/G agarose resin 




3.2.1 Ubiquitylation of Ciz1 
Analysis of the amino acid sequence of Ciz1 in Mus musculus revealed the presence 
of 37 lysine residues (Fig. 13) as well as a putative D-box. 
 
Figure 13: Identification of putative ubiquitylation sites in Ciz1 
Representation of all lysine residues located within the murine form of Ciz1, denoting 
putative ubiquitylation sites. A putative destruction box was also identified.  
Due to the large number of putative ubiquitylation sites within the Ciz1 protein, it was 
not feasible to mutate each individual site to create GFP-Ciz1 mutants. Ubiquitylation 



















































3.2.2 Identifying soluble pools containing Ciz1 protein 
 
Figure 14: Fractionation of cells to determine Ciz1 localisation 
Differential cellular fractionations was performed by treating cells with final 
concentrations of 1% Triton X-100, 0.5M NaCl and 1x DNaseI (diluted in 1x 
DNaseI buffer). Between each step, samples were centrifuged. After treatment with 
DNaseI, centrifugation occurred at 17 000xg. Prior centrifugations occurred at 10 
000xg. An aliquot of the supernatant was removed for analysis and the remaining 
supernatant was removed. A similar method was used to prepare fractionated cells 
for analysis by immunofluorescence. 
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To perform investigations into ubiquitylation status of Ciz1, it was first necessary to 
identify if there were soluble pools of Ciz1 within cell extracts. Ciz1 is a protein that 
is integral to the nuclear matrix, a cellular fraction that resists high salt and nuclease 
treatment (Ainscough et al., 2007). Using cellular fractionation (Fig. 14), western 
blotting was used to identify whether soluble Ciz1 could be obtained for both 
endogenous Ciz1 and over-expressed recombinant Ciz1. Results show that localisation 
of the transfected GFP-WT-Ciz1 (Fig. 15B) is identical to the distribution of the 
endogenous protein (Fig. 15A). Both endogenous and exogenous Ciz1 localise 
predominantly to the nuclear matrix and could therefore be used in further studies 
such as observing the effects of mutants on localisation. The Ciz1 protein was found 
to be soluble in detergent and high salt fractions. These results concur with those 
previously obtained by Ainscough et al. (2007) who fractionated cells in a similar 
manner and found that Ciz1 associated with the nuclear matrix co-localised with 
newly synthesised DNA during the S phase. 
 
Figure 15: Identification of Ciz1 localisation 
(A) Soluble protein pools following cell fractionation (see Figure 14) showing 
endogenous Ciz1. The detergent used was 1% Triton X-100 and the salt was 0.5M 
NaCl. (B) Soluble protein pools following fractionation showing both transfected 
GFP-WT-Ciz1 and endogenous Ciz1 can be found in the same soluble pools 












3.2.3 Determining whether Ciz1 is ubiquitylated 
Having identified the soluble pools in which the Ciz1 protein can be found, it was 
possible to perform experiments with Ciz1 and ubiquitin. Considering the multiple 
possible methods of determining whether Ciz1 is ubiquitylated (section 3.2). the 
following experiments were performed using His-tagged ubiquitin followed by 
immobilisation with Ni
2+
-NTA, thus eliminating the need to use antibodies at multiple 
stages to form immune complexes and indirectly capturing proteins via these 
antibodies. 
These experiments involved both transfection with His-Ub to detect endogenous Ciz1 
and co-transfection with GFP-WT-Ciz1 and His-Ub. For these experiments, two 
soluble pools of protein were used for the initial experiments: the detergent soluble 
(referred to as the low salt extract) and the high salt soluble pools. This was performed 
in order to observe whether there might be a difference in ubiquitylation events of 
Ciz1 between separate cellular compartments. Effects of addition of the proteasomal 
inhibitor MG132 were also tested. The results obtained from the low salt extracts, 
largely containing cytoplasmic proteins, of cells with only endogenous Ciz1 protein 




Figure 16: Determining ubiquitylation status of endogenous Ciz1 in the low salt 
fraction 
Cells were transfected with His-Ub or GFP as indicated, 24 hours prior to harvesting. 
MG132 was added at a concentration of 10µM as indicated four hours prior to 
harvesting. The low salt cellular extract was applied to Ni
2+
-NTA resin and allowed to 
bind. (A) Protein load for identifying endogenous Ciz1. (B) Ciz1 following Ni
2+
-NTA 
immobilisation of the extract shown in (A).  
 
In Figure 16A, low salt extracts of samples are shown before binding to the Ni
2+
-NTA 
resin. It is immediately apparent that a difference exists between samples treated with 
MG132 (lanes 2 and 4) and those that were not (lanes 1 and 3). In the samples with no 
His-Ub but treated with MG132 (lane 2), a dark band appears at a slightly higher 
molecular weight to that of the darkest band in lane 3, containing the sample 
transfected with His-Ub but not treated with MG132. Interestingly, in the sample 
transfected with His-Ub and treated with MG132 (lane 4), there are two distinct bands 



















































in lanes 3 and 4, there are multiple faint bands at higher molecular weights (see 
arrows) that are visible in both lanes. The detection of higher laddered molecular 
weight Ciz1 protein when transfected with His-Ub (lanes 3 and 4) is attributed to 
poly-ubiquitylation (Bloom and Pagano, 2005). After binding to the Ni
2+
-NTA, shown 
in Figure 16B, Ciz1 is only detected in samples treated with MG132 (lanes 2 and 4), 
with a significantly more prominent band in lane 4 containing the sample that had also 
been transfected with His-Ub. The observation that a small amount of Ciz1 is present 
after binding to Ni
2+
-NTA when no His-Ub is present in lane 2, is attributable to the 
fact that Ciz1 has three zinc fingers (Mitsui et al., 1999) that are capable of binding to 
the resin (Hanas et al., 2005). Addition of MG132 appears to have an effect on the 
ubiquitylation of endogenous Ciz1 as might be expected if Ciz1 is indeed a substrate 
of the 26S proteasome. This also suggests that there is a dependency on this chemical 
for the detection of ubiquitylation of this protein. 
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Figure 17 shows the high salt extracts of samples from the same experiment as that 
shown in Figure 16. In Figure 17A, which shows samples before binding to the Ni
2+
-
NTA, a similar banding pattern is observed in all lanes to that observed in Figure 16A. 
However, there is no apparent laddered higher molecular weight Ciz1 protein when 
transfected with His-Ub (lanes 3 and 4, Figure 17A) as there was in the corresponding 
samples in Figure 16A. It is important to consider the possibility that these higher 
molecular weight bands are simply below the limit of detection of the system. 
Interestingly, there is a marked difference between these samples after binding to the 
 
Figure 17: Determining ubiquitylation status of endogenous Ciz1 in the high salt 
fraction 
Cells were transfected with GFP or His-Ub as indicated, 24 hours prior to harvesting. 
MG132 was added at a final concentration of 10µM as indicated, four hours prior to 
harvesting. The high salt cellular extract was applied to Ni
2+
-NTA resin and allowed 
to bind. (A) Protein load for identifying endogenous Ciz1. (B) Ciz1 following Ni
2+
-





















































-NTA resin (Fig. 17B) in lanes 3 and 4 when compared to the corresponding 
samples of the low salt extracts in Figure 16B. In lane 3 of Figure 16B it shows that in 
the absence of MG132, samples with His-Ub do not appear to bind to the Ni
2+
-NTA 
resin, suggesting a dependency on this drug for detection of Ciz1 as mentioned 
previously. However, in lane 3 of Figure 17B it shows that with the corresponding 
high salt extract sample, a lot more Ciz1 is bound to the Ni
2+
-NTA resin than when 
MG132 is present (lane 4). This suggests that the dependency on MG132 for detection 
observed in the low salt extract does not apply for the high salt extract; indeed it 
suggests the exact opposite. 




The data presented above are consistent with the ubiquitylation of Ciz1. As Ciz1 has 
been shown to be active in the late G1 to early S phases, the most obvious candidate 
for the E3 ligase responsible for Ciz1 ubiquitylation is APC/C
Cdh1
; which is the 
principle E3 ligase responsible for the degradation of cyclins during the G1 phase. 
Supporting this, Ciz1 contains a putative RXXL destruction box that is utilised by 
APC/C
Cdh1
 for substrate recognition (section 1.3). The presence of this putative D-box 
has been identified in multiple species, supporting the theory that this is a functional 
destruction box (Fig. 18). 
As Cdh1 is the component of the APC/C
Cdh1
 complex responsible for binding targets, 
the following experiments to determine whether this complex is responsible for the 
ubiquitylation of Ciz1 were performed using Cdh1 alone. In order to test whether 
Cdh1 can actually bind Ciz1, GST-tagged Cdh1 and Ciz1 were produced. 
Immobilisation of the GST-Ciz1 or GST-Cdh1 were used for protein interaction 
assays. For these experiments, the N-terminal fragment of Ciz1 containing the 
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replication activity, termed N471, was used. A mutant of N471 was also produced 
where the consensus sequence ‘RXXL’ for the destruction box was mutated to 
‘AXXA’ using whole plasmid mutagenesis. Success of this procedure was confirmed 
by DNA sequencing (Eurofins Genomics). Also, agarose gel electrophoresis was 
performed following DpnI digestion of the wild-type vector to confirm successful 
amplification of the plasmid. 
 
Figure 18: The D-box sequence in Ciz1 is highly conserved in ten species 
BLAST searches of the N-terminal region of Ciz1 identified that the RXXL motif was 
conserved in mammalia. Primary sequence alignments were performed using Clustal 
(www.ebi.ac.uk). 
 
Following DNA sequencing, plasmids containing a GST-tagged Ciz1 or GST-Cdh1 
were transformed into BL-21 E. coli cells which were then grown to maximise protein 
production. The proteins of interest were then purified, followed by cleavage from the 
GST tag in some cases by 3C protease and protein-protein binding assays were set up.  
Mus musculus                 LLNG-PMLQRALLLQ 
Tupaia chinensis             LLNG-PLLQRALLLQ 
Cricetulus griseus           LLNG-SMLQRALLLQ 
Heterocephalus glaber        LLNG-SMLQRALLLQ 
Rattus norvegicus            LLNG-SMLQRALLLQ 
Homo sapiens                 LLNG-SMLQRALLLQ 
Gorilla gorilla gorilla      LLNG-SMLQRALLLQ 
Callithrix jacchus           LLNG-SMLQRALLLQ 
Cavia porcellus              LLNG-SMLQRALLLQ 
Fukomys damarensis           LLNG-SMLQRALLLQ 
Amazona aestival       LLNANPMLQRALLMQ 
Chelonia mydas        LLNANPMLQRTLLLQ 





Figure 19: Protein-protein interaction studies between Cdh1 and WT-Ciz1-N471  
Proteins were bound for an hour before washing. Samples were taken before (input) 
and after (recovered) binding, with GST used as a control for non-specific tag 
interactions. Three volumes of the soluble protein being bound were used. Samples 
were removed to show protein loads (upper panels). (A) GST-Cdh1 was immobilised 
and increasing amounts of Ciz1 added. Recovered Ciz1 bound to Cdh1 was found for 
all protein concentrations (lower panel). (B) Reactions were performed as for (A) 
except GST-Ciz1 was immobilised and increasing amounts of Cdh1 added. Recovered 
Cdh1 bound to Ciz1 was found for all protein concentrations (lower panel). 
In an attempt to minimise false- positive and negative results; each experiment was 
performed in two ways. For example, Cdh1 was bound to immobilised N471 and 
N471 was bound to immobilised Cdh1 in parallel reciprocal experiments. Results 
shown in Figures 19A and B show that after binding, proteins of interest were 
recovered. This suggests that Ciz1 binds to Cdh1 and Cdh1 binds to Ciz1. Increasing 
volumes of N471 added show that this binding occurs in a concentration dependent 
manner (lanes 2-4, Fig. 19A). Decreasing volumes of Cdh1 added demonstrate this 
same phenomenon (lanes 2-4, Fig. 19B).  
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Figure 20: Protein-protein interaction studies between Cdh1 and N471-D-box 
Proteins were bound for an hour before washing. Samples were taken before (input) 
and after (recovered) binding, with GST used as a control. Samples were removed to 
show protein loads (upper panels). (A) GST-Cdh1 was immobilised and Ciz1 was 
added. Ciz1 was not recovered after binding (lower panel). (B) Reactions were 
performed as for (A) except GST-D-box-Ciz1 was immobilised and Cdh1 added. 
Cdh1 was not recovered after binding (lower panel).  
Having found that the putative destruction box within Ciz1, denoted by the ‘RXXL’ 
motif, is highly conserved (Fig. 18) and that results shown in Figure 19 suggest that 
Ciz1 is a target of the APC/C
Cdh1
 complex; it seems likely that Cdh1 binds to Ciz1 via 
this putative D-box. In order to investigate whether this is indeed the case, an N471-
D-box protein mutant was created by whole plasmid mutagenesis and confirmed by 
DNA sequencing (Eurofins Genomics) followed by protein production using BL-21 E. 
coli cells as described previously. The experiment was set up in the same manner as 
that also described previously (Fig. 19). Results show that no binding occurs between 
Cdh1 and the D-box mutant (Figs. 20A and B).The results in Figures 19 and 20 
suggest that Cdh1 and Ciz1 interact and that this interaction is mediated by the 
putative destruction box; supporting the hypothesis that APC/C
Cdh1
 is a viable 
candidate for being the E3 ligase responsible for ubiquitylating Ciz1. The fact that no 
binding occurs when the D-box is mutated is a strong indicator as this sequence is 


































One of the major systems used to degrade proteins involved in cell cycle regulation is 
the ubiquitin proteasome system which uses many proteins such as ubiquitin as a 
signaling system and E3 ligases to recognize substrates. Previous studies have 
observed that Ciz1 could be degraded by this system as addition of a proteasomal 
inhibitor MG132 resulted in recovery of Ciz1 protein levels (Fig. 5) (Copeland, 
unpublished data). This was also oobserved in this study (section 3.1). A quantitative 
proteomic survey of in vivo ubiquitylation sites by mass spectrometry identified a 
lysine residue at position 830 in human Ciz1 that was found to form an isopeptide 
bond with a glycine residue of ubiquitin (Wagner et al., 2011); identifying that Ciz1 is 
ubiquitylated. The work presented here supports this observation and due to detection 
of multiple bands detected in the His-ubiquitin pull-down assays suggest that Ciz1 is 
poly-ubiquitylated.  
The use of His-Ub and Ni
2+
-NTA immobilization to identify ubiquitylated proteins 
has been widely used (Kirkpatrick et al., 2005). The low salt fraction in these studies 
showed distinct bands of higher molecular weight than Ciz1 (Fig. 16A), creating a 
laddering effect in the samples seen previously with other polyubiquitylated proteins 
(Bloom and Pagano, 2005). Following Ni
2+
-NTA immobilization, Ciz1 was only 
recovered in the presence of MG132. This suggests that there is some dependency on 
MG132 although the prominent laddering present in the absence of the proteasomal 
inhibitor prior to immobilization suggests otherwise. A small amount of Ciz1 was also 
recovered in the presence of this chemical in the absence of His-Ub. This is attributed 
to the fact that Ciz1 has three zinc fingers (Mitsui et al., 1999) which are capable of 
binding to Ni
2+
 (Hanas et al., 2005).  This would also explain why Ciz1 was recovered 
in all the samples when cells were transfected with GFP-WT-Ciz1. Two dominant 
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bands were observed in the sample with addition of MG132 in the presence of His-Ub 
prior to Ni
2+
-NTA immobilization which could indicate a dependency on MG132 and 
that the absence of recovered Ciz1 after immobilization when no proteasomal 
inhibitor is present could simply be due to lower levels of the protein that were 
undetectable when developing the western blot at the optimum exposure. Longer 
exposures resulted in the blot quickly becoming completely black such that no 
individual bands were visible. 
In the high salt soluble pools, fewer bands of higher molecular weight were observed 
prior to Ni
2+
-NTA immobilization although one such band was observed after 
immobilization in the sample where no MG132 was added. As with the low salt 
soluble samples, two distinct bands are observed with the addition of MG132, 
although only one band is observed in the absence of the chemical. This supports 
expectations that inhibition of the proteasome should result in increased levels of 
protein substrates, which in turn supports the theory that Ciz1 is a substrate of the 
ubiquitin proteasome system. These double bands could also indicate that high levels 
of Ciz1 protein are mono-ubiquitylated, which could be attributed to a function 
separate to that of marking for degradation (Hicke, 2001) since the latter requires 
substrates to be polyubiquitylated. However, after Ni
2+
-NTA immobilization, a lot 
more Ciz1 was recovered in the absence of MG132 than in its presence unlike the 
recovery of the protein in the low salt soluble pool. This could indicate that there is a 
difference in Ciz1 regulation between separate cell compartments. However, this 
experiment would need to be repeated to confirm this observation, preferably using a 
slightly modified method to minimize binding of Ciz1 to the Ni
2+




Considering that Ciz1 is known to function during the late G1 phase and it has been 
shown here that Ciz1 is likely a substrate of APC/C
Cdh1
; it is possible that the results 
obtained here suggesting that Ciz1 is poly-ubiquitylated are representative of Ciz1 
poly-ubiquitylation to differing degrees by APC/C
Cdh1
. 
Having confirmed that Ciz1 is indeed ubiquitylated as suggested by previous 
experiments (Wagner et al., 2011) and the observation that inhibition of the 
proteasome resulted in increased protein levels (Fig. 5); identification of the possible 
E3 ligase responsible for this reaction was investigated. As it was previously observed 
that Ciz1 contains a destruction box sequence and the fact that Ciz1 is largely active 
during the G1 and S phases, APC/C
Cdh1
 was considered as a possible candidate. 
Results obtained suggest that Cdh1 does bind to Ciz1 and that Ciz1 also binds to 
Cdh1. Both interactions occur in a concentration dependent manner. These interaction 
studies suggest that APC/C
Cdh1
 is the E3 ligase responsible for the ubiquitylation of 
Ciz1. This suggestion is supported by further in vitro protein-protein interaction 
studies between Cdh1 and a mutant form of Ciz1 where the putative destruction box 
had been mutated. No binding occurred between these two proteins; not only 
supporting the theory that the E3 ligase is APC/C
Cdh1
; but also that the putative 
destruction box identified is also functional. Further experimentation is required to 
determine whether Ciz1 stability is affected by loss of this D-box in vivo. 
Results presented here suggest that Ciz1 protein levels are regulated by ubiquitylation 
mediated by APC/C
Cdh1
 but this requires additional experimentation to confirm this in 
vivo. Experiments using His-Ub suggest that Ciz1 is poly-ubiquitylated; supporting 
the previous observation made in section 3.1 that inhibition of the 26S proteasome 
results in increased Ciz1 levels. This suggests that Ciz1 is degraded by the ubiquitin 
proteasome system. Using in vitro protein interaction studies, Cdh1 has been shown to 
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bind Ciz1, suggesting that Ciz1 ubiquitylation is mediated by Cdh1. This is supported 
by the evidence provided by further in vitro protein interaction studies using Cdh1 and 
Ciz1 with a mutated putative D-box. These demonstrated that in the absence of the 
RXXL sequence, binding no longer occurred between Ciz1 and Cdh1. This also 
suggests that the RXXL sequence, often used by APC/C
Cdh1
 to recognize its 
















3.3 INVESTIGATION OF A POTENTIAL CDK-PHOSPHORYLATION SITE 
INVOLVED IN CIZ1 STABILITY 
3.3.1 Investigation of Ciz1-N471 as a substrate of cyclin A-CDK2, in vitro 
The use of in vitro kinase assays allows a preliminary view of the relationship 
between an enzyme and a substrate. Having previously observed that Ciz1 is a 
substrate of cyclin A-CDK2 (Copeland et al., 2015), in vitro kinase assays were 
performed and phosphorylation status of S331, was determined. A phospo-specific 
antibody was also raised against this site. Another site, T293, which has already been 
confirmed to be phosphorylated by cyclin A-CDK2, was used as a positive control. 
Several concentrations of Ciz1-N471 were used in an attempt to discover the kinetic 
profiles of the reaction between cyclin A-CDK2 and Ciz1-N471; at the two chosen 
sites T293 and S331.   
Preliminary results shown in Figure 5 (unpublished data, Copeland) as well as the 
results obtained in this study (section 3.1) suggest that Ciz1 levels increase after 
phosphorylation. However, it has also been established that phosphorylation of Ciz1 at 
T144, T192 and T293 inhibits Ciz1 DNA replication function (Copeland et al., 2015). 
These apparent contradictory observations remain to be fully resolved. This may be 
due to the S331 site within Ciz1 that is also readily phosphorylated by cyclin A-CDK2 
but does not inhibit Ciz1 function although phosphorylation of other sites in Ciz1 in 






3.3.2 Localisation of Ciz1 containing the S331A and S331D mutations is 
unchanged 
It has been well documented that mutations of phosphorylation sites within proteins 
can lead to aberrant sub-cellular localisation causing various disease states (Hung and 
Link, 2011). Ciz1 has been shown to largely associate with the nuclear matrix 
(Ainscough et al., 2007). However, considering the fourteen putative CDK 
phosphorylation sites it is possible that one of the putative phosphorylation sites in 
Ciz1 can alter sub-cellular localisation when phosphorylated. As it has been indicated 
that phosphorylation of S331 might have a significant function (Copeland et al., 
2015), sub-cellular localisation of Ciz1 was investigated using GFP-WT-Ciz1 to 
observe normal sub-cellular localisation; GFP-S331A-Ciz1 to observe any potential 
effects on localisation if the protein is unphosphorylable at S331; and GFP-S331D-
Ciz1, a phosphomimetic mutant, to observe whether phosphorylation at this site alters 
sub-cellular localisation. This initial experiment was performed as it is possible that 
the mutated Ciz1 protein may not physically be in the right location to be a substrate 
for cyclin A-CDK2. The GFP-S331A-Ciz1 mutant was created using whole plasmid 
mutagenesis by PCR followed by DNA sequencing (Eurofins Genomics) to confirm 
the successful introduction of the mutation. 
These experiments were performed by transfecting cells with the GFP-tagged Ciz1 
constructs containing the wild-type protein, an unphosphorylated protein and a protein 
with a phosphomimetic residue. Cells were then fractionated (Fig. 14) (section 3.2.2) 
followed by western blotting (Fig. 21) and immunofluorescence (Figs. 22-23). The use 
of these constructs is a viable method of determining Ciz1 localisation as it was 
previously determined that localisation of GFP-WT-Ciz1 is the same as that of 
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endogenous Ciz1 (Fig. 15). 
 
 
Figure 21: Mutation of S331 does not alter sub-cellular localisation 
Cells were fractionated 24 hours after transfection with GFP-tagged Ciz1 constructs 
containing either the wild type, S331D mutant or S331A mutant. The detergent 
used was 1% Triton X-100 and the final salt concentration was 0.5M NaCl. Cells 
were treated with DNaseI for 1 hour. (A) Fractionation of cells transfected with WT 
Ciz1. (B) Fractionation of cells transfected with Ciz1 containing the S331D 
mutation . (C) As with (B), except cells are transfected with the S331A mutant. 
 
Fractionation of transfected cells followed by western blotting (Fig. 21) shows that 
phosphorylation status does not alter the sub-cellular localisation of the Ciz1 protein 
(Figs. 21A and B): it is largely associated with the nuclear matrix. Sub-cellular 
localisation of both mutants is the same as that of the wild-type protein and the 
endogenous protein as seen previously in Figure 15 and by Ainscough et al. (2007). 
Ciz1 and all mutants tested also associated with the nuclear matrix but a sub-fraction 
was also found in detergent and high salt soluble pools. Determination of sub-cellular 
localisation of Ciz1 mutants by fractionation and western blotting is consistent and 
localisation of the recombinant wild-type protein appears to be the same as that of the 



















Figure 22: Fractionation of cells reveals WT-Ciz1 is largely associated with the 
nuclear matrix 
Immunofluorescence images showing nuclei transfected with GFP-WT-Ciz1 after 
undergoing the same fractionation steps as performed for the western blots revealing 
that WT-Ciz1 is largely found at the nuclear matrix. 
 
In order to further confirm this observation, fractionation of cells after transfection 
with GFP-WT-Ciz1 followed by immunofluorescence was also performed (Fig. 22), 
which supported results obtained by western blotting (Fig. 21A). 
3.3.3 The anti-pS331 antibody: confirming specificity 
Prior to investigation of the phosphorylation status of the S331 site, confirmation that 
the S331 phospho-specific antibody recognises its intended target only was required. 




































Having already synthesised the S331A-Ciz1-N471 protein, an in vitro kinase assay 
was performed using this protein and western blots were probed with the anti-pS331 
and anti-pT293 antibodies (Fig. 23). The T293 phospho-specific antibody has 
previously been characterised (Copeland et al., 2015). 
 
Figure 23: Characterisation of the α-pS331 antibody 
Final concentrations of 2µM of S331A-Ciz1-N471 and 5nM cyclin A-CDK2 were 
used. The anti-pS331 antibody did not detect anything whereas the anti-pT293 
antibody did; as expected. 
Results obtained for the S331A-Ciz1-N471 protein (Fig. 23) reveal that the anti-pS331 
antibody does not recognise this mutated site as expected. Probing with anti-pT293 
and anti-N471 confirmed the presence of the protein as well as the fact that the cyclin 
A-CDK2 did phosphorylate at the T293 site. These results suggest that the anti-pS331 
antibody does indeed recognise the required site. Considering that sub-cellular 
localisation is not altered, it is possible that this mutation might have an effect on 
protein function rather than localisation. This is supported by the fact that this site is 
within the C-terminal domain of the full-length protein which is responsible for 
protein function. 
3.3.4 Ciz1-N471 is phosphorylated at sites T293 and S331 by cyclin A-CDK2 
Determining the rate of a reaction can be complicated when multiple reactants are 
involved as it is necessary to measure the concentrations of each one at the same time; 
and when determining rates of reaction can lead to some complex mathematics. 
S331A-N471 
pS331  





Having to measure multiple reactants can also increase the margin of error of the 
entire system. It also complicates determining the correct parameters required for 
solving the rate of reaction (Schnell and Mendoza, 2004). In order to simplify this, the 
initial concentration of one of the reactants is much higher than that of the other 
reactant. This means that as the reaction progresses, the concentration of the reactant 
in excess changes only minutely compared to the concentration of the other reactant 
and can therefore be considered as a constant during the first moments of the reaction; 
thus leaving only one variable left. This condition is known as a pseudo-first order 
condition, as it appears that the rate of reaction is only dependent on one variable 
(Malatesta, 2005); making determination of the rate of reaction simpler to determine. 
For this reason, the following experiments were set up such that the initial substrate 
concentrations (Ciz1) were in excess. Small samples were removed from the reaction 
at specific time points to determine phosphorylation levels. These were added to 2x 
SDS-PAGE loading buffer and boiled immediately after removal in order to inhibit 
further enzyme activity. The reactions were performed at 37
o
C. 
Since different antibodies were used in these experiments, with unknown binding 
affinities, conditions were established such that basic rates of phosphorylation could 
be determined for a range of Ciz1 concentrations. This allowed initial rates to be 
determined for each site at a range of concentrations and the rates to be plotted against 
the concentrations. These conditions were established by taking the highest 
concentration of Ciz1 tested (2µM) and performing the in vitro kinase assay. When 
detecting phosphorylation levels, optimal concentrations of the antibodies were used 
and the blot was exposed until the upper detection limit of the equipment was reached. 
This exposure time was then used as the acquisition time for all the other Ciz1 





Figure 24: Phosphorylation of T293 and S331 in WT-Ciz1-N471 by cyclin A-
CDK2 increases with time 
Cyclin A-CDK2 was added at t=0. (A) Western blots were produced using anti-
pT293, anti-pS331, pIMAGO and anti-Ciz1. The total Ciz1 protein (detected by α-
N471) was used as a loading control. (B) Phosphorylated protein levels as detected by 
anti-pT293 were quantified using ImageLab software, signal intensity was plotted 
against time and shown in a line graph. (C) Phosphorylated protein levels as detected 






















































































Figure 25: Phosphorylation of S331 in DDD-Ciz1-N471 by cyclin A-CDK2 
increases with time  
This experiment was performed at 37
o
C with cyclin A-CDK2 introduced to the system 
at t=0. Each reaction started with a total volume of 200µl and at each time point, 25µl 
were removed. Samples were boiled in 2x SDS-PAGE loading buffer for 10 minutes 
immediately after removal from the reaction. (A) Western blots were produced using 
anti-pT293, anti-pS331, pIMAGO and anti-Ciz1. The total Ciz1 protein (detected by 
anti-Ciz1) was used as a loading control. (B) Phosphorylated protein levels as detected 
by anti-pS331 were quantified and a graph was produced. 
Initial experiments were conducted using the proteins WT-Ciz1-N471 (Fig. 24) and 
the protein DDD-Ciz1-N471 (Fig. 25) containing phosphomimetic mutations of sites 
T144, T192 and T293 which were detected using the anti-Ciz1 N471 and anti-Ciz1 
pT293 antibodies. As can be observed in Figure 24A and Figure 25A, two bands are 
detected by the anti-N471 antibody. This is due to the fact that this antibody also 
recognises Hsp70 that co-purifies with recombinant Ciz1 constructs. Quantifications 









































Phosphorylation at S331 B 
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as Ciz1 is exposed to cyclin A-CDK2, it is continuously phosphorylated. However, a 
direct comparison between these two sites cannot be performed by using these two 
graphs as the binding affinities of the two antibodies used are unknown. It is clear in 
Figure 25A, that the anti-pT293 antibody does not detect anything as expected but that 
the anti-pS331 antibody does. This shows that phosphorylation at T293 does not 
prevent consequent phosphorylation of S331. Another phospho-protein detection 
system, the pIMAGO system (Expedeon) was also tested in order to view total levels 
of phosphorylated protein.  
As can be observed in both Figures 24A and 25A, the pIMAGO detection system 
(Expedeon) does not seem to be very sensitive to this phosphorylated protein. This 
system specifically detects phosphorylated molecules. Unlike phospho-specific 
antibodies, it does not bind to only specific amino acid sequences so is able to detect 
phosphorylation at any site within a protein. It is clear when using the phospho-
specific antibodies that Ciz1 is phosphorylated by cyclin A-CDK2 at both the T293 
and the S331 sites. An observation to consider is that at 20 minutes, phosphorylation 
levels of DDD-N471 at the S331 site appear to have decreased (Fig. 25B), although 
when comparing pS331 levels and N471 levels, a likely explanation for this 
occurrence is simply that there is less protein in this sample compared to the samples 




3.3.5 Determining phosphorylation rate profiles of Ciz1-N471 by cyclin A-CDK2 
at T293 and S331 
As both phospho-specific antibodies have been shown to recognise their specific sites, 
it was possible to explore whether differences in phosphorylation rates of these two 
sites could be observed using in vitro kinase assays. To construct a graphical 
representation of the kinetics rate profile of these phosphorylated sites, several kinase 
assays were performed using various concentrations of WT-Ciz1-N471 ranging 
between 50nM and 2µM and 5nM of cyclin A-CDK2. Once these assays had been 
performed, samples were used to produce western blots which were probed with anti-
pT293 and anti-pS331 (Fig. 26). Protein levels were quantified and plotted on graphs 
(Fig. 27).  
 
Figure 26: Phosphorylation levels at T293 and S331 using increasing substrate 
concentrations 
For each substrate (WT Ciz1) concentration, in vitro kinase assays were performed 
twice. A concentration of 5nM of cyclin A-CDK2 was used for all assays. Western 















Figure 27: Graphs representing increasing phosphorylation levels as initial 
substrate concentration increases 
These graphs were used to calculate initial velocities for each substrate concentration. 
(A) Average increases in phosphorylation levels at T293 over time using initial 
substrate concentrations between 200nM and 2μM. (B) Average increases in 
phosphorylation levels at S331 over time using initial substrate concentrations 
between 50nM and 2µM. 
 
Although direct comparisons between the rates of phosphorylation of Ciz1 at these 
two sites cannot be made due to the unknown binding affinities of the two anitbodies 
used; it is interesting to note that the S331 phosphomimetic antibody (Fig. 27B) was 
able to detect low levels of phosphorylation when Ciz1 was present at a concentration 












































































(Fig. 27A). It would be interesting to determine binding affinities of these two 
antibodies as at this stage, it is not possible to determine whether the S331 phospho-
specific antibody simply has a stronger binding affinity than its T293 counterpart or 
whether S331 is more readily phosphorylated by cyclin A-CDK2 than T293. 
However, taking this into consideration, it is also interesting to note that when Ciz1 is 
present at a concentration of 2uM, the T293 phospho-specific antibody (Fig. 27A) 
detects higher levels of phosphorylated protein than the S331 phospho-specific 
antibody (Fig. 27B). If binding increases in a linear fashion up to 2uM, this suggests 
that T293 is phosphorylated to a higher level than S331. Further investigation is 
required to determine whether this is true though, using an alternative method to using 
those phosphor-specific antibodies such as the use of radiolabelled isotopes.  
3.3.6 Discussion 
Mutation of a single site within a protein that is sometimes phosphorylated can have 
drastic effects on function and sub-cellular localisation which can lead to some serious 
diseases (Hung and Link, 2011, Shin et al., 2002, Gregory et al., 2003). Preliminary 
work suggests that the S331 site within Ciz1 is phosphorylated at an earlier stage of 
the cell cycle (late G1) than the T293 site (S phase) and that Ciz1 is a substrate of 
cyclin E-CDK2 (Copeland et al., 2015); although this requires more thorough 
investigation. Since experiments described earlier suggested that APC/C
Cdh1
, which is 
active during the late G1 phase, is a potential E3 ligase responsible for ubiquitylation 
of Ciz1 and in turn its degradation; S331 was marked as a potential CDK-mediated 
phosphorylation site that, when phosphorylated, increases protein stability according 
to results presented in Figure 5 and section 3.1. In order to investigate whether S331 
does play a role in protein stability, several experiments were performed designed to 
determine the effects if this site is mutated. 
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Prior to investigating whether S331 may be involved in contributing to protein 
stability, it was confirmed that phosphorylation of this site does not alter sub-cellular 
localisation. Results show that S331 is phosphorylated by cyclin A-CDK2 (Fig. 24A). 
Further work is required such as using site directed mutagenesis of individual CDK 
sites and radiolabelled ATP to probe more precisely the kinetic behaviour of Ciz1 
phosphorylation. In addition, cyclin E-CDK2 may play an important role in 
phosphorylation of the S331 site during the late G1 phase, conferring a degree of 
protection from degradation. This could be assessed first using in vitro kinase assays 
to determine whether S331 can be phosphorylated by cyclin E-CDK2 and then using 
cell based assays by synchronising cell populations and observing the effects on 
phosphorylation of specific sites within Ciz1 such as S331 if cyclin E-CDK2 is 
inhibited. 
As previously stated, preliminary work suggests that S331 is phosphorylated during 
the late G1 phase whereas T293 appears to be phosphorylated later on during the S 
phase. Since the main cyclin active during the G1-S phase transition is cyclin E bound 
to CDK2, it would have been interesting to observe phosphorylation rates of T293 and 
S331 and compare them with those obtained when using cyclin A-CDK2. 
Unfortunately, we were unable to purify cyclin E-CDK2 despite several attempts that 
would have enabled further investigation and comparison of cyclin-CDK2 complex 
specificities. 
As it was demonstrated using in vitro means that the S331 site within Ciz1 can be 
phosphorylated by cyclin A-CDK2, it remains a possibility that this site could 
contribute to protein stability. As there are several lysine residues situated nearby the 
S331 site (Fig. 13), it is possible that S331 could contribute to protein stability by 
influencing ubiquitylation of these sites or by more indirect methods.  
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Results obtained do not show conclusively that S331 is involved in contributing to 
protein stability. However, we have clearly demonstrated that S331 is phosphorylated 
by cyclin A-CDK2 in vitro and this provides an additional opportunity to test the role 
of phosphorylation of this site in vivo. In order to do this, further in vivo work would 
need to be performed using both the S331A mutation and the S331 phosphomimetic 
mutation. However, results do indicate that this function is indeed a viable possibility 
as mutation of this site does not lead to altered sub-cellular localisation and it is 
















4. GENERAL DISCUSSION 
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4.1 CDK-mediated phosphorylation of Ciz1 
Many proteins involved in the regulation of the cell cycle are known to be 
phosphorylated by CDKs. These phosphorylation events have a number of different 
effects on the altered protein; including contributing to protein stability and marking 
the protein for degradation, usually by the ubiquitin proteasome system. One such 
modified protein that is known to be protected from ubiquitin-mediated degradation 
when phosphorylated, which has been well-documented is Cdc6 (Duursma and 
Agami, 2005, Mailand and Diffley, 2005). Cdc6 is one of the major proteins involved 
in preparing for the replication of DNA by being a component of the pre-replication 
complex. When Cdc6 is phosphorylated by cyclin E-CDK2 at residues serine 54 and 
serine 74, the protein is no longer targeted by the E3 ligase APC/C
Cdh1
. 
Conversely, phosphorylation of proteins can also act as a mark for degradation. One 
such protein is p27
Kip1
, a non-specific CDK inhibitor able to inhibit all cyclin-CDK 
complexes required during the G1 phase and entry into the S phase. It also has several 
other functions attributed to it including being involved in cellular differentiation and 
tumour suppression (Sgambato et al., 2000). The protein p27
Kip1
 has been shown to be 
phosphorylated by CDK2 at residue threonine 187, marking it for degradation by the 
E3 ligase SCF
Skp2
 (Tsvetkov et al., 1999, Auld et al., 2007). 
 Ciz1 has been known to associate with cyclin A-CDK2 and thought to associate with 
cyclin E-CDK2 for some years now (Copeland et al., 2010b); however, it has only 
recently been shown that Ciz1 is also a substrate of cyclin A-CDK2 (Copeland et al., 
2015). Cyclin A-CDK2 has the ability to phosphorylate Ciz1 at residues threonine 
144, threonine 192 and threonine 293. These phosphorylation events do not affect 
protein stability; instead they block replisome formation and inhibit the initiation of 
DNA replication. They also prevent cyclin A-CDK2 from binding to the Ciz1 protein. 
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Interestingly, preliminary work using chemical inhibitors of CDK activity 
(roscovitine) and the 26S proteasome used to degrade proteins (MG132) suggested 
that phosphorylation of Ciz1 also increases protein stability (Fig. 5) (Copeland, 
unpublished data). In order to identify whether this is indeed true and, if so, determine 
which CDK-mediated phosphorylation site(s) is responsible; experiments were 
designed using mouse 3T3 fibroblasts transfected with plasmid constructs containing a 
GFP tag and phosphomimetic mutations of Ciz1. To do this, all putative CDK-
mediated phosphorylation sites (fourteen in total) were identified. Experiments were 
also set up to observe the effects of different concentrations of the chemical inhibitors 
on endogenous Ciz1 protein as well as the wild type recombinant protein to identify 
the optimal conditions in which to perform these experiments. 
Unfortunately, no significant, reproducible effects were observed on recombinant 
GFP-Ciz1 protein levels at any of the tested chemical concentrations (Figs. 7-10). 
However, inhibition of CDK activity did result in decreased endogenous Ciz1 protein 
levels (Fig. 7) suggesting decreased protein stability as a consequence of the absence 
of certain phosphorylation events. Protein levels were partially recovered in the 
presence of the 26S proteasome inhibitor (lane 5, Fig. 7), also suggesting that Ciz1 is 
degraded by the ubiquitin proteasome system. As preliminary work had also suggested 
that knockdown of cyclin A by using α-ccna2 siRNA in a synchronised population of 
cells had a similar effect on Ciz1 protein levels as addition of the CDK inhibitor 
roscovitine (Fig. 5A); this method was also tested. However, no significant, 
reproducible effects were again observed (Figs. 11 and 12). Several possible 
explanations exist, which could explain why results obtained do not agree with those 
obtained during the preliminary work. The most likely is a problem encountered in the 
lab at the time these experiments were performed. During this time, all cells used did 
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not synchronise very well; with some populations not surviving the process at all and 
others where only very few cells survived. Cell populations that did not undergo the 
process of synchronisation did not survive for very long either. One possible reason 
behind this is that the cells used were coming to the end of their life-span. However, 
during other experiments performed at a later date, cells seemed to synchronise quite 
well and survived much longer. 
Although the chemical CDK inhibitor roscovitine was shown to reduce endogenous 
Ciz1 levels, suggesting that Ciz1 stabilisation occurs by phosphorylation; the same 
effects were not observed for recombinant GFP-Ciz1 at the concentrations tested. A 
possible explanation for this could be that concentrations of chemical inhibitors used 
were not in the correct range, likely due to the much higher level of protein 
expression. This would suggest that protein levels were likely affected but due to the 
very high Ciz1 protein concentrations, these changes were undetectable. New stock 
solutions of roscovitine were prepared a number of times during this process so it is 
unlikely that the cause of these unexpected results was due to the use of old aliquots 
that were no longer as chemically active. 
Cyclin A knockdown experiments were performed both in synchronous and 
asynchronous populations of cells and no effects on Ciz1 levels were observed. These 
experiments would need to be repeated as sample sizes used here were very small. 
However, results presented here suggest that not only does CDK-mediated 
phosphorylation of Ciz1 inhibit its function in DNA replication (Copeland et al., 
2015), but that CDK-mediated phosphorylation also stabilises the protein. 
Having encountered an inability to identify the optimal conditions in which to perform 
experiments using chemical inhibitors of CDK activity (roscovitine) and the 26S 
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proteasome (MG132), it was therefore not possible to use the fourteen 
phosphomimetic mutants designed to discover which site(s) within Ciz1, if any, is 
responsible for increasing protein stability when phosphorylated using the methods 
originally planned. Using an alternative method; that of cyclin A knockdown by 
transfection with α-ccna2 siRNA; also did not yield expected results and so could not 
be used. Even so, if this second method had worked as expected, it would not have 
been possible to repeat these experiments many times due to the presence of fourteen 
mutants and the necessity of synchronising cell populations, which by design requires 
several days to complete as cells are left for 48 hours after reaching 100% confluency 
before being released back into the cell cycle. 
4.2 Ciz1 is a target of the ubiquitin proteasome system 
As preliminary work has suggested that inhibiting the 26S proteasome results in Ciz1 
protein levels being increased (Fig. 5) (Copeland, unpublished data), it seems that 
Ciz1 is also a target of the ubiquitin proteasome system. Results obtained (Figs. 7-10 
and 12) do indicate some increase in protein levels with addition of MG132 
supporting this. Investigations were therefore performed to identify whether Ciz1 is 
ubiquitylated or not using plasmids constructs containing ubiquitin and a tag. This was 
because the Mus musculus form of Ciz1 contains 37 lysine residues, which are 
putative ubiquitylation sites (Pickart, 2001). Due to the large number of sites, it was 
not feasible to mutate each site individually to investigate which site(s) is 
ubiquitylated and so a more general method was used to identify ubiquitylation. 
Experiments performed were conducted using His-tagged ubiquitin. Results obtained 
did yield some interesting observations. Using two fractions of cells to detect 
ubiquitylated Ciz1, pull down assays were performed in order to detect both 
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endogenous Ciz1 and recombinant Ciz1. It was found that although endogenous Ciz1 
appeared to be pulled down when bound to His-Ub, recombinant Ciz1 was pulled 
down even in the absence of His-Ub. This was explained by the fact that Ciz1 has 
three zinc fingers in the C-terminal domain (Mitsui et al., 1999) that are able to bind to 
the Ni
2+
 (Hanas et al., 2005), which forms part of the Ni
2+
-NTA resin used to 
immobilise proteins of interest. As a result, later experiments were performed using 
higher concentrations of imidazole so as to increase the amount of His-Ub complexed 
with recombinant Ciz1 eluted. This did not improve results however and so it was not 
possible to perform further experiments using recombinant Ciz1 to detect 
ubiquitylation status by co-transfecting cells with His-Ub and GFP-Ciz1. However, 
results obtained using endogenous Ciz1 did suggest that, as expected, Ciz1 is 
ubiquitylated. At least two bands are observed in the presence of MG132. This is 
consistent with poly-ubiquitylation (Bloom and Pagano, 2005), although is not 
definitive. This also shows that inhibition of the 26S proteasome is required to 
efficiently recover Ciz1 bound by His-Ub. 
Interestingly, there appeared to be a slight difference in MG132 dependency between 
the low and high salt fractions used to detect endogenous Ciz1 (Figs. 16A, B and 17A, 
B). In the low salt extracts, Ciz1 seemed only to be pulled down when the 26S 
proteasome was inhibited whereas in the high salt extracts, more Ciz1 was pulled 
down when the 26S proteasome was not inhibited. Unfortunately, due to the previous 
problems encountered when using the chemical MG132 and the fact that Ciz1 itself 
can bind to the Ni
2+
-NTA resin, it is not clear whether or not this apparent difference 
on dependency is reproducible at this time. Further work is therefore required to 
determine this. A possible addition to the protocol used could be the addition of 
chemical inhibitors of deubiquitylating enzymes (DUB) in an attempt to increase 
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ubiquitylation levels of proteins; although investigation into these inhibitors is still in 
the early stages (Ndubaku and Tsui, 2015). Inhibition of deubiquitylating enzymes is 
possible using N-ethylmaleimide that covalently inactivates the nucleophilic thiol 
residue of DUBs (Huang et al., 2006, Jacobson et al., 2009). 
As results obtained using pull down assays of endogenous Ciz1 protein and His-Ub 
revealed that Ciz1 is ubiquitylated as expected, an investigation into the E3 ligase(s) 
responsible for this was performed using in vitro protein-protein interaction studies 
with GST-tagged proteins of interest. Of the two main E3 ligase complexes 
responsible for targeting proteins involved in cell cycle regulation for degradation, 
APC/C and SCF (Vodermaier, 2004), the most likely candidate for ubiquitylation of 
Ciz1 is APC/C due, in part, to the identification of a putative destruction box (D-box) 
identified within the Ciz1 sequence. This D-box sequence is a motif found in many 
targets of the APC/C which is recognised by this E3 ligase (Castro et al., 2005). The 
APC/C has two main activating proteins that also confer substrate specificity: Cdc20 
and Cdh1 which bind to complex in a sequential manner. Cdh1 binds the APC/C 
towards the end of mitosis and stays there until it is phosphorylated and degraded at 
the end of the G1 phase (Li and Zhang, 2009, Kramer et al., 2000). As such, 
APC/C
Cdh1
 was considered a likely candidate. 
Ciz1-N471 was found to bind to immobilised GST-Cdh1 in a concentration dependent 
manner. Similar results were obtained when Cdh1 was bound to GST-Ciz1-N471 (Fig. 
19). These results suggested that APC/C
Cdh1
 is indeed an E3 ligase responsible for the 
ubiquitylation of Ciz1. As Ciz1 has been observed to have a putative D-box, a mutant 
of Ciz1-N471 was created such that the ‘RXXL’ sequence that makes up the D-box 
was mutated to ‘AXXA’. As expected, when the D-box in Ciz1 is mutated, no binding 
occurs between Ciz1-N471 and Cdh1; indicating that APC/C
Cdh1
 binds to Ciz1 via the 
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D-box and further supporting the possibility that APC/C
Cdh1
 is an E3 ligase 
responsible for Ciz1 degradation. Further work will need to be performed to verify 
these interactions using more in depth protein-protein interaction studies such as 
protein microarrays where proteins are bound to an immobilised sheet although there 
are several other methods available as well (Hall et al., 2007, Rao et al., 2014). In vivo 
work would also need to be performed to observe the effects on Ciz1 if, for example, 
Cdh1 is knocked down. Cdh1 binding to substrates leads to poly-ubiquitylation (Rape 
et al., 2006) and results presented here suggest that Ciz1 is poly-ubiquitylated. It 
should also be noted that CDK-mediated phosphorylation of Ciz1 appears to 
contribute to protein stability; an attribute also found in other substrates of APC/C
Cdh1
 
(Mailand and Diffley, 2005, Holt et al., 2008, Lee et al., 2007). 
The fact that APC/C
Cdh1
 appears to be able to ubiquitylate Ciz1 and that this E3 ligase 
is only active until the late G1 phase implies that Ciz1 protein levels must be tightly 
regulated during this stage. Considering that the function of Ciz1 is to aid cyclin A-
CDK2 with the initiation of DNA replication and the observation that APC/C
Cdh1
 can 
ubiquitylate Ciz1; this suggests that Ciz1 protein levels are tightly regulated such that 
DNA replication is not initiated until the checkpoint has been passed when restrictions 
by APC/C
Cdh1
 are removed, allowing Ciz1 levels to rise until all licensed sites have 
been fired. In order to prevent re-replication of DNA, cyclin A-CDK2 then 
phosphorylates Ciz1 (Copeland et al., 2015), blocking interactions between these 
proteins and inhibiting further rounds of initiation of DNA replication.  
As it has been suggested that phosphorylation of Ciz1 could also contribute to protein 
stabilisation, this could mean that a balance is in place between Ciz1 phosphorylation 
and APC/C
Cdh1
 degradation. Further work is required to understand exactly how Ciz1 
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levels are regulated as results obtained suggest that there are multiple levels of control 
which act according to whichever stage the cell cycle is in. 
4.3 The S331 site in Ciz1 is phosphorylated by cyclin A-CDK2 
It has previously been established that not only is Ciz1 a binding partner of cyclin A-
CDK2 but that it is also a substrate of this enzyme complex. Phosphorylation of Ciz1 
at sites T144, T192 and T293 by cyclin A-CDK2 results in a reduced ability to initiate 
DNA replication by inhibiting replisome formation (Copeland et al., 2015). 
Preliminary work had suggested that this site, S331, might be involved in protein 
stability and so the kinase assays would demonstrate whether or not, this site can be 
phosphorylated by cyclin A-CDK2. A study of the interactions between the S331 site 
and the cyclin A-CDK2 was performed, after confirmation that phosphorylation of 
S331 does not alter Ciz1 sub-cellular localisation. 
An initial study of the S331 site revealed that mutation of this site, such that the site 
could no longer be phosphorylated or where it appeared to be in a constant state of 
phosphorylation, does not lead to altered sub-cellular localisation of the protein (Fig. 
21). Mutations of proteins are known to be able to cause aberrant localisation, which 
can result in serious consequences (Hung and Link, 2011). However, it has also been 
shown that the absence of the N-terminal domain of Ciz1, which contains the nuclear 
localisation signal, does not inhibit initiation of DNA replication (Ainscough et al., 
2007), suggesting that even if mutation of the S331 site did result in altered sub-
cellular localisation, the replicative function of Ciz1 might still be intact. 
With the S331 site appearing not to be involved in protein localisation; it is possible 
that this site does contribute to protein stability. Results obtained from in vitro kinase 
assays revealed that the S331 site is indeed phosphorylated by cyclin A-CDK2 (Fig. 
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24). Further experiments would need to be performed to assess enzyme kinetics of 
phosphorylation of Ciz1 between cyclin E-CDK2 and cyclin A-CDK2.  
Investigation of phosphorylation rates of the T293 and S331 sites could be useful. As 
the cyclin E-CDK2 complex is active earlier in the G1 phase than cyclin A-CDK2, 
differences in specificity could contribute to stabilisation of Ciz1. Any differences 
would demonstrate which of these cyclin-CDK complexes preferentially 
phosphorylate which sites and would give an indication as to when during the cell 
cycle each site is modified. Unfortunately, attempts at growing BL-21 E. coli cultures 
with plasmid vectors containing cyclin E failed to grow to sufficient levels. 
In order to test whether the S331 site could be involved in protein stability, pull down 
assays were performed using His-Ub and various forms of recombinant Ciz1 to assess 
ubiquitylation status. If the phosphomimetic mutant (S331D) was not ubiquitylated or 
was ubiquitylated to a lesser degree, this would have suggested that this site is 
responsible for protein stability. However, despite using a slightly modified protocol, 
recombinant Ciz1 was still being pulled down in the absence of His-Ub, attributed to 
the presence of the zinc fingers within the protein. It was therefore not possible to 
determine if S331 does a play a role in protein stabilisation. It is a possible function as 
it has now been demonstrated to be phosphorylated by cyclin A-CDK2. 
4.4 A model of Ciz1 function  
According to evidence and theories presented in this thesis, also based on published 
data and preliminary work, the following model of Ciz1 regulation is proposed (Fig. 
28). During the G1 phase, replication complex assembly begins. As cyclin E-CDK2 
activity rises, CMG complex assembly begins with DDK activation. This is the phase 
of the cell cycle where Ciz1 levels are rising correlating with the increase in kinase 
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activity. Ciz1 protein levels are regulated by phosphorylation events and the UPS. The 
results presented here are consistent with the APC/C
Cdh1
 complex regulating Ciz1 
function via substrate recognition via the destruction box within Ciz1. The balance 
between Ciz1 protective phosphorylation by CDK2 and Ciz1 ubiquitylation by 
APC/C
Cdh1
 during the G1 phase until the cell is ready for entry into the S phase may 
contribute to genome stability through regulation of Ciz1 protein levels. 
Once the cell is ready to enter the S phase, Ciz1 binds to cyclin A-CDK2 and together, 
this complex promotes the initiation of DNA replication (Copeland et al., 2010b) 
leading to replisome formation. Ciz1 protein levels are reaching their maximum level 
at this phase of the cell cycle (Copeland et al., 2015) potentially due to the degradation 
of the Cdh1 subunit by SCF at the G1/S phase transition (Kramer et al., 2000). As the 
cell progresses through the S phase, in order to prevent re-replication of DNA, cyclin 
A-CDK2 gradually phosphorylates Ciz1 at sites T144, T192 and T293; causing 
dissociation from the cyclin-CDK complex (Copeland et al., 2015). Ciz1 levels are 
then maintained throughout the remainder of the cell cycle and fall during early G1 in 
the subsequent cell cycle. This cycling of Ciz1 protein levels mirrors the relative CDK 
activity present in the cell. 
Ciz1 protein over-expression has been associated with several types of cancer. The 
fine tuning of Ciz1 levels by opposing phosphorylations and UPS-mediated 
degradation could contribute to regulation of Ciz1 function, thereby preventing 
untimely DNA replication that is associated with replication stress. These mechanisms 




Figure 28: Proposed model for phosphorylation and ubiquitylation events of Ciz1 
during the G1 and S phases  
Compiling all evidence obtained from previous studies and in this study, this model is 
proposed for the events that occur during the G1 and S phases regarding Ciz1. 
 
4.5 Ciz1 in cancer 
Dysregulated Ciz1 has been observed in multiple cancer types (Higgins et al., 2012, 
Okumura et al., 2011, Wang et al., 2014a). If the model presented here in Figure 28 is 
correct, albeit incomplete, it is fairly clear how dysregulated Ciz1 could lead to a 
dysregulated cell cycle and eventually lead to the development of cancer. Control of 
the initiation of DNA replication is paramount to a healthy cell cycle as the following 
processes should not be allowed to occur if the previous steps have not been 
completed or the cell is not in the position to be able to divide in order to produce two 
healthy daughter cells. Loss of this control can lead to cancer. Considering that Ciz1 is 
involved in regulating the initiation of DNA replication, understanding how this 


























cancers and potentially what treatments could be performed such that this 
dysregulation is reversed or counteracted in such a way that Ciz1 protein levels return 
to normal and also function normally. This knowledge would also allow a better 
understanding of whether the dysregulated Ciz1 protein observed in these cancers is a 
cause or a consequence of this state. 
If dysregulated Ciz1 is a cause of cancer, understanding the cause of dysregulation 
could lead to the identification of a novel therapeutic target. Understanding how Ciz1 
is normally regulated is therefore extremely important. If dysregulated Ciz1 is a 
consequence of cancer, it is possible that treating the consequence could ameliorate 
the cancer and, together with treatment of the initial cause, lead to a complete 
response instead of a partial response and could even decrease to probability of 
recurrence and development of resistance. 
Targetting the UPS has lead to some surprising success as the drugs appear to target 
cancer cells only (Shen et al., 2013). If this therapy were to be administered together 
with another drug that would also affect Ciz1 protein stability, Ciz1 stability would be 
regulated from two directions, increasing the chance of having a positive effect and 
reverting the cell back to its normal state. According to results presented here, if the 
putative CDK-phosphorylation site(s) responsible for contributing to protein stability 
can be identified, inhibition of phosphorylation at this site(s) would lead to increased 
protein degradation, a desired consequence considering that in cancers, Ciz1 is 
observed to be up-regulated (section 1. 7). 
4.6 Future work 
Further work is required to determine which sites within Ciz1, if any, contribute to 
protein stability. The S331 site is a possible candidate for this function but in vivo 
106 
 
work using a phosphomimetic mutant and a mutant where phosphorylation is not 
possible is required in order to determine what the function of phosphorylation at this 
site is. It would also be interesting to observe if ubiquitylation status of Ciz1 is altered 
if S331 is mutated. This can be taken further by investigating whether mutation of 
other putative CDK-mediated phosphorylation sites affects ubiquitylation of Ciz1. 
Confirmation of APC/C
Cdh1
 as an E3 ligase responsible for Ciz1 degradation is also 
required. This can be determined with the use of Cdh1 knock downs and observing 
effects on Ciz1 protein levels. Further investigation of the putative D-box should be 
performed in vivo as well to demonstrate that this sequence is not only functional in 
vitro. 
Investigations into whether Ciz1 is a substrate of cyclin E-CDK2 in vivo should also 
be performed. Synchronised cell experiments would be able to show whether the S331 
site is phosphorylated prior to the T293 site and which cyclin-CDK complexes are 
primarily responsible for these events. In vitro kinase assays with cyclin A-CDK2 
using higher Ciz1 concentrations and radioisotopes could also be performed to 
determine if enzyme kinetics occur according to Michaelis-Menten kinetics and if so, 
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